Details of Disease

General Information of Disease (ID: DISJ5D6U)

• Disease Name: Childhood acute lymphoblastic leukemia
• Synonyms: acute lymphoblastic leukemia (ALL); acute lymphoblastic leukaemia (ALL); pediatric acute lymphoid leukemia; pediatric acute lymphogenous leukemia; pediatric acute lymphocytic leukemia (ALL); pediatric acute lymphocytic leukemia; pediatric acute lymphoblastic leukemia; pediatric ALL; paediatric acute lymphoid leukaemia; paediatric acute lymphogenous leukaemia; paediatric acute lymphocytic leukaemia (ALL); paediatric acute lymphocytic leukaemia; paediatric acute lymphoblastic leukaemia; paediatric ALL; childhood precursor lymphoblastic leukemia; childhood precursor lymphoblastic leukaemia; childhood acute lymphoid leukemia; childhood acute lymphoid leukaemia; childhood acute lymphogenous leukemia; childhood acute lymphogenous leukaemia; childhood acute lymphocytic leukemia; childhood acute lymphocytic leukaemia; childhood acute lymphoblastic leukemia; childhood ALL
• Definition: An acute lymphoblastic leukemia occurring during childhood. The majority of cases are B-acute lymphoblastic leukemias. Approximately 15% of the cases are T-acute lymphoblastic leukemias.
• Disease Hierarchy:
  DIS51BK2: Pediatric lymphoma
  DISS7D1V: leukaemia
  DIS87TGM: Acute lymphoblastic leukaemia
  DISJ5D6U: Childhood acute lymphoblastic leukemia
• Disease Identifiers:
  MONDO ID: MONDO_0000870
  MESH ID: D054198
  UMLS CUI: C0023452
  MedGen ID: 44122

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Methotrexate	DM2TEOL	Approved	Small molecular drug	[1]
Pegaspargase	DM2S26S	Approved	NA	[2]
Prednisone	DM2HG4X	Approved	Small molecular drug	[3]
Vincristine	DMINOX3	Approved	Small molecular drug	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 175 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BCL6	TTC9YX5	Limited	Altered Expression	[5]
CDK2	TT7HF4W	Limited	Genetic Variation	[6]
CDK6	TTO0FDJ	Limited	Biomarker	[7]
CDKN2C	TTBRUGA	Limited	Altered Expression	[8]
CYP1A2	TTS1DTU	Limited	Biomarker	[9]
CYP1B1	TTI84H7	Limited	Biomarker	[9]
DCK	TTJOCE4	Limited	Biomarker	[10]
FBXW7	TT29KY7	Limited	Genetic Variation	[11]
FCGRT	TTKLPHO	Limited	Genetic Variation	[12]
FUT4	TTNV1KZ	Limited	Biomarker	[13]
GGH	TTZJRL0	Limited	Genetic Variation	[14]
HDAC1	TT6R7JZ	Limited	Biomarker	[15]
IDH1	TTV2A1R	Limited	Biomarker	[9]
IKZF2	TTKT5NV	Limited	Biomarker	[16]
IKZF3	TTCZVFZ	Limited	Biomarker	[16]
IL3RA	TTENHJ0	Limited	Genetic Variation	[17]
MAP3K10	TT9FN4J	Limited	Genetic Variation	[18]
MAP3K20	TTTUZ3O	Limited	Altered Expression	[19]
MERTK	TTO7LKR	Limited	Biomarker	[20]
NME1	TTDY8JH	Limited	Altered Expression	[21]
NOTCH1	TTB1STW	Limited	Genetic Variation	[22]
NRP1	TTIPJCB	Limited	Biomarker	[23]
OPRK1	TTQW87Y	Limited	Altered Expression	[24]
SLCO1B1	TTFGXEB	Limited	Genetic Variation	[25]
TCF3	TTULOD8	Limited	Genetic Variation	[26]
AURKB	TT9RTBL	Disputed	Altered Expression	[27]
CBL	TT7QT13	Disputed	Genetic Variation	[28]
CBS	TTVZJ7G	Disputed	Genetic Variation	[29]
CD33	TTJVYO3	Disputed	Biomarker	[30]
CRYZ	TTP6UO8	Disputed	Genetic Variation	[31]
FAT1	TTGUJYV	Disputed	Biomarker	[32]
KITLG	TTDJ51N	Disputed	Biomarker	[33]
PMEL	TT8MK59	Disputed	Genetic Variation	[34]
PTPRC	TTUS45N	Disputed	Biomarker	[35]
TOP2A	TTCGY2K	Disputed	Genetic Variation	[36]
ABCC2	TTFLHJV	moderate	Genetic Variation	[37]
ABCC4	TTUEAFL	moderate	Genetic Variation	[38]
CASP8	TT6SZNG	moderate	Altered Expression	[39]
CD37	TTFCW29	moderate	Altered Expression	[40]
CYP3A4	TTWP7HQ	moderate	Biomarker	[41]
FHIT	TTMS54D	moderate	Posttranslational Modification	[42]
IL7	TT8FRMO	moderate	Biomarker	[43]
MDM4	TT9OUDQ	moderate	Biomarker	[44]
NR1I3	TTRANFM	moderate	Biomarker	[45]
P2RY8	TT84EWY	moderate	Biomarker	[46]
PML	TTLH9NY	moderate	Genetic Variation	[47]
ABCC1	TTOI92F	Strong	Altered Expression	[48]
ABCC3	TTVLG21	Strong	Altered Expression	[49]
ABCG2	TTIMJ02	Strong	Altered Expression	[50]
ALPI	TTHYMUV	Strong	Altered Expression	[51]
ANPEP	TTPHMWB	Strong	Altered Expression	[30]
ATIC	TT9NVXQ	Strong	Posttranslational Modification	[52]
ATRAID	TTFLIKM	Strong	Genetic Variation	[53]
BIRC7	TTHZ8TA	Strong	Biomarker	[54]
BLK	TTNDSC3	Strong	Biomarker	[55]
BTG1	TTL7N2W	Strong	Genetic Variation	[56]
CA5A	TT75WPO	Strong	Biomarker	[57]
CASP10	TTX5HEK	Strong	Altered Expression	[58]
CD160	TTOFEAS	Strong	Biomarker	[59]
CD34	TTZAVYN	Strong	Altered Expression	[60]
CD38	TTPURFN	Strong	Biomarker	[61]
CD52	TTQT5S9	Strong	Biomarker	[62]
CD58	TT5KSBY	Strong	Biomarker	[63]
CD83	TTT9MRQ	Strong	Altered Expression	[64]
CEACAM6	TTIGH2W	Strong	Altered Expression	[65]
CEL	TTTRNQW	Strong	Genetic Variation	[66]
CES1	TTMF541	Strong	Biomarker	[67]
CLCF1	TTI6V13	Strong	Altered Expression	[68]
CNTFR	TTT2F9E	Strong	Biomarker	[69]
CR1	TTEA8OW	Strong	Biomarker	[70]
CRHR1	TT7EFHR	Strong	Genetic Variation	[71]
CTCFL	TTY0RZT	Strong	Altered Expression	[72]
CTSG	TTQAJF1	Strong	Biomarker	[73]
DHFR	TTYZVDJ	Strong	Biomarker	[74]
DLL1	TT9CFQD	Strong	Genetic Variation	[75]
DSG3	TTEO4P8	Strong	Biomarker	[76]
EBI3	TTJF68X	Strong	Genetic Variation	[77]
EPHA1	TTLFZVU	Strong	Posttranslational Modification	[78]
EPOR	TTAUX24	Strong	Altered Expression	[79]
F8	TT1290U	Strong	Genetic Variation	[80]
FABP3	TT3TGLR	Strong	Biomarker	[81]
FDXR	TT3W4IX	Strong	Biomarker	[82]
FER	TTRA9G0	Strong	Biomarker	[83]
GART	TTEXB9Z	Strong	Altered Expression	[84]
GEM	TTAZF9M	Strong	Genetic Variation	[85]
GOT1	TTU507L	Strong	Altered Expression	[86]
GPR132	TTNBW4F	Strong	Altered Expression	[87]
GRIA1	TTVPQTF	Strong	Genetic Variation	[88]
HAL	TTXQOZW	Strong	Biomarker	[89]
HCK	TT42OGM	Strong	Biomarker	[90]
HOXA5	TTXSVQP	Strong	Altered Expression	[91]
HPGDS	TTCYE56	Strong	Genetic Variation	[92]
IL1RL1	TT4GZA4	Strong	Biomarker	[93]
IL7R	TTAWI51	Strong	Biomarker	[94]
JAK1	TT6DM01	Strong	Genetic Variation	[22]
JAK3	TTT7PJU	Strong	Biomarker	[95]
KIR2DL1	TT4UXPE	Strong	Biomarker	[96]
KIR3DL2	TTQH3N0	Strong	Genetic Variation	[97]
KMT5A	TTGC95K	Strong	Genetic Variation	[98]
LAIR1	TTSI7A8	Strong	Biomarker	[99]
LILRB2	TTHC6XU	Strong	Biomarker	[100]
LIPA	TTS8T1M	Strong	Genetic Variation	[101]
LMO2	TTFX379	Strong	Biomarker	[102]
LRP1	TTF2V7I	Strong	Biomarker	[103]
LSS	TT7O8ZA	Strong	Biomarker	[104]
LTB	TTHQ6US	Strong	Altered Expression	[105]
MAN2A1	TT34DCN	Strong	Genetic Variation	[106]
MAP2K2	TT8H9GB	Strong	Genetic Variation	[107]
MAP4	TT0VFPN	Strong	Genetic Variation	[108]
MARCKS	TTHRM39	Strong	Biomarker	[109]
MPO	TTVCZPI	Strong	Altered Expression	[110]
MSI2	TTTXQF6	Strong	Altered Expression	[111]
MSR1	TT2TDH9	Strong	Genetic Variation	[112]
NAAA	TTMN4HY	Strong	Biomarker	[113]
NEDD8	TTNDC4K	Strong	Biomarker	[114]
OTC	TT5KIO9	Strong	Biomarker	[115]
P2RY14	TT72OKI	Strong	Altered Expression	[116]
PAM	TTF4ZPC	Strong	Genetic Variation	[117]
PIM2	TT69J2Z	Strong	Altered Expression	[118]
PKD2L1	TTAHD89	Strong	Biomarker	[119]
PLK4	TTGPNZQ	Strong	Biomarker	[120]
PNP	TTMCF1Y	Strong	Altered Expression	[121]
PSMB6	TT8EPLT	Strong	Genetic Variation	[75]
PTK7	TTXH2ZN	Strong	Biomarker	[122]
PTP4A3	TT7YM8D	Strong	Biomarker	[123]
PTPN6	TT369M5	Strong	Biomarker	[124]
RARG	TT1Q3IE	Strong	Genetic Variation	[125]
REL	TT1ZCTH	Strong	Biomarker	[126]
ROR1	TTDEJAU	Strong	Altered Expression	[127]
RPSA	TTLUW5B	Strong	Biomarker	[103]
S100A4	TTPR5SX	Strong	Posttranslational Modification	[128]
SCT	TTOBVIN	Strong	Biomarker	[129]
SLC11A2	TT2IS7P	Strong	Genetic Variation	[130]
SLC19A1	TT09I7D	Strong	Biomarker	[74]
SLC1A3	TT8WRDA	Strong	Altered Expression	[131]
SLC29A1	TTLXAKE	Strong	Biomarker	[132]
SLCO1A2	TTUGD21	Strong	Genetic Variation	[133]
SMYD2	TT7YJFO	Strong	Altered Expression	[134]
SNAP25	TTYQWA0	Strong	Biomarker	[135]
SPHK2	TTCN0M9	Strong	Biomarker	[136]
SPRY1	TT0PSN6	Strong	Biomarker	[137]
SRD5A2	TTT02K8	Strong	Biomarker	[138]
SYK	TT2HUPM	Strong	Biomarker	[139]
TBL1XR1	TTYXT16	Strong	Biomarker	[140]
TCL1A	TTUKRDV	Strong	Genetic Variation	[141]
THRB	TTGER3L	Strong	Posttranslational Modification	[142]
TLR6	TTWRI8V	Strong	Genetic Variation	[143]
TMPRSS11D	TTWHYC8	Strong	Genetic Variation	[144]
TMPRSS6	TTL9KE7	Strong	Genetic Variation	[130]
TNFRSF13C	TT7NJSE	Strong	Biomarker	[145]
TRB	TT84HCW	Strong	Genetic Variation	[146]
TRBC1	TT1DHW2	Strong	Genetic Variation	[146]
TRIM24	TT9Q7AE	Strong	Biomarker	[147]
TYRO3	TTIEMFN	Strong	Altered Expression	[148]
USP33	TT4E85Q	Strong	Altered Expression	[149]
WNT7A	TT8NARC	Strong	Altered Expression	[150]
WWP1	TTBWMKT	Strong	Biomarker	[151]
ZAP70	TTUMHT8	Strong	Altered Expression	[152]
AICDA	TTKRTP6	Definitive	Altered Expression	[153]
BTLA	TTER58P	Definitive	Biomarker	[154]
CD46	TTMS7DF	Definitive	Genetic Variation	[155]
CYP2E1	TTWVHQ5	Definitive	Genetic Variation	[156]
DPYD	TTZPS91	Definitive	Genetic Variation	[157]
EIF2AK4	TT9U4EP	Definitive	Biomarker	[158]
EPHB4	TTI4ZX2	Definitive	Genetic Variation	[159]
HDAC8	TTT6LFV	Definitive	Altered Expression	[160]
IRS1	TTAJSQ0	Definitive	Biomarker	[161]
KIR2DS1	TTVWAGF	Definitive	Biomarker	[162]
MTAP	TTDBX7N	Definitive	Genetic Variation	[163]
PRAME	TTPH7T0	Definitive	Altered Expression	[164]
RARA	TTW38KT	Definitive	Genetic Variation	[165]
SERPINC1	TT4QPUL	Definitive	Altered Expression	[166]
TNFRSF9	TTPW9LJ	Definitive	Biomarker	[167]
WEE1	TTJFOAL	Definitive	Biomarker	[168]
XPO1	TTCJUR4	Definitive	Biomarker	[169]

This Disease Is Related to 8 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCA3	DT2T6VQ	Limited	Altered Expression	[170]
SLCO6A1	DTIFXNS	Limited	Genetic Variation	[171]
ABCC5	DTYVM24	Disputed	Genetic Variation	[172]
ABCB5	DTKVEXO	Strong	Altered Expression	[173]
SLC26A3	DTN1FMD	Strong	Genetic Variation	[174]
SLC27A5	DT0TQS3	Strong	Genetic Variation	[66]
SLC28A3	DT4YL5R	Strong	Genetic Variation	[175]
ABCA2	DTJ4NEG	Definitive	Altered Expression	[176]

This Disease Is Related to 12 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP2C8	DES5XRU	Limited	Biomarker	[9]
CYP4F3	DEFCMPI	Strong	Biomarker	[177]
EPHX1	DELB4KP	Strong	Biomarker	[178]
FADS1	DE05S8C	Strong	Genetic Variation	[179]
HPRT1	DEVXTP5	Strong	Genetic Variation	[180]
MTRR	DE6NIY9	Strong	Altered Expression	[181]
NNMT	DECVGJ3	Strong	Genetic Variation	[182]
SCLY	DEH4TD6	Strong	Altered Expression	[183]
UBASH3B	DE10BJ5	Strong	Altered Expression	[137]
UGT1A6	DESD26P	Strong	Genetic Variation	[125]
FPGS	DECWT2V	Definitive	Genetic Variation	[184]
NT5C2	DE1DOKJ	Definitive	Genetic Variation	[185]

This Disease Is Related to 287 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
A2ML1	OTWNUXIS	Limited	Altered Expression	[186]
AFF1	OTT2C78E	Limited	Genetic Variation	[187]
AFF3	OTR0705Z	Limited	Biomarker	[188]
ARID5B	OTUQ4CQY	Limited	Altered Expression	[189]
ARNT	OTMSIEZY	Limited	Biomarker	[9]
B3GAT1	OTXFP98E	Limited	Biomarker	[59]
BCL9	OTRBIPR4	Limited	Altered Expression	[190]
CALM2	OTNYA92F	Limited	Genetic Variation	[191]
CBFB	OTIAC6W4	Limited	Genetic Variation	[192]
CD79A	OTOJC8DV	Limited	Biomarker	[193]
CEBPE	OTKZA25M	Limited	Genetic Variation	[194]
CILK1	OTWOYEYP	Limited	Altered Expression	[19]
CKS1B	OTNUPLUJ	Limited	Biomarker	[195]
CKS2	OTPTMHIV	Limited	Altered Expression	[195]
CORO1A	OTVAZOHC	Limited	Posttranslational Modification	[196]
CSN2	OT22C0PD	Limited	Biomarker	[197]
GATA1	OTX1R7O1	Limited	Altered Expression	[198]
GSTK1	OTDNGWAF	Limited	Genetic Variation	[171]
KLHL1	OTAX6SAD	Limited	Altered Expression	[199]
MARCKSL1	OT13J2FM	Limited	Altered Expression	[200]
MEF2D	OT7CEIG0	Limited	Altered Expression	[190]
MLLT1	OT41UZU5	Limited	Biomarker	[201]
MLLT10	OTURMDV7	Limited	Genetic Variation	[202]
MPEG1	OT7DAO0F	Limited	Genetic Variation	[203]
MPST	OTCDPH5D	Limited	Genetic Variation	[18]
MSTO1	OT37XCNP	Limited	Genetic Variation	[18]
MYH11	OTVNVWY3	Limited	Biomarker	[204]
NUDC	OT073JKX	Limited	Biomarker	[205]
PACSIN2	OTC2R00C	Limited	Genetic Variation	[206]
PAG1	OTFOJUIQ	Limited	Altered Expression	[207]
PICALM	OTQVRPMQ	Limited	Genetic Variation	[202]
POTEF	OTV3WXYE	Limited	Biomarker	[208]
PRDM14	OTWZKY4L	Limited	Biomarker	[209]
PRPS1	OTN3A6CN	Limited	Biomarker	[210]
RAG1	OTV131E4	Limited	Genetic Variation	[211]
RALGAPB	OTY8CGA3	Limited	Altered Expression	[186]
RB1	OT9VMY7B	Limited	Biomarker	[212]
SEPTIN4	OTD16B30	Limited	Biomarker	[210]
SMARCB1	OT2LP7LJ	Limited	Biomarker	[213]
SNAP91	OTE3EXWZ	Limited	Genetic Variation	[191]
SYCE1L	OTXU44F3	Limited	Altered Expression	[199]
TFR2	OTMYCCEO	Limited	Genetic Variation	[214]
TLX3	OTBUHHK3	Limited	Posttranslational Modification	[215]
CDX2	OTCG4TSY	Disputed	Altered Expression	[216]
FANCL	OTJC7QPQ	Disputed	Genetic Variation	[217]
GFI1	OT9HB9H8	Disputed	Biomarker	[218]
HLA-DPB1	OTW8JHU2	Disputed	Biomarker	[219]
HOXA9	OTKNK5H0	Disputed	Biomarker	[220]
MRPL28	OT4LUTZU	Disputed	Posttranslational Modification	[221]
NXT1	OT0VO6AY	Disputed	Posttranslational Modification	[221]
OPN1LW	OTFNUZ7O	Disputed	Altered Expression	[207]
PCBP4	OTDLL4NB	Disputed	Altered Expression	[207]
PRF1	OTFVXD7H	Disputed	Genetic Variation	[222]
RMDN2	OTK5WSFI	Disputed	Altered Expression	[223]
STIL	OT9799VN	Disputed	Genetic Variation	[34]
SUB1	OTK71JYU	Disputed	Posttranslational Modification	[221]
ARHGAP24	OTCQCEZS	moderate	Genetic Variation	[224]
ARR3	OTRZ00CH	moderate	Biomarker	[45]
ATN1	OTNZFLKY	moderate	Biomarker	[225]
CXADR	OT9ZP02A	moderate	Biomarker	[45]
EBF1	OTZ61YYH	moderate	Biomarker	[212]
MSH3	OTD3YPVL	moderate	Biomarker	[44]
MVP	OTJGHJRB	moderate	Biomarker	[103]
NUDT15	OTX8SZOT	moderate	Biomarker	[226]
SPG7	OT8OY9ST	moderate	Biomarker	[45]
TP73	OT0LUO47	moderate	Posttranslational Modification	[227]
TRIM13	OTQIUACB	moderate	Biomarker	[45]
ACCS	OTHIHI9D	Strong	Genetic Variation	[228]
ADA2	OTGCV24S	Strong	Biomarker	[229]
ADAMTSL4	OTBILJMW	Strong	Biomarker	[137]
ADAMTSL5	OTQAGNQP	Strong	Posttranslational Modification	[230]
AEBP1	OTBI1RZ6	Strong	Altered Expression	[231]
AFF4	OTTL5Y8R	Strong	Biomarker	[232]
AFM	OTPOR8IO	Strong	Biomarker	[122]
AIF1L	OTDEOB80	Strong	Biomarker	[233]
ARHGEF1	OTXU4HBW	Strong	Biomarker	[234]
ARPP21	OTWXZN5I	Strong	Genetic Variation	[235]
ATF5	OT03QCLM	Strong	Genetic Variation	[236]
ATF7IP	OTU6ZA7F	Strong	Genetic Variation	[237]
ATP6	OTPHOGLX	Strong	Genetic Variation	[238]
ATP8	OTYQQR53	Strong	Genetic Variation	[238]
AUTS2	OTAEXHSC	Strong	Biomarker	[239]
BAALC	OTUZSRVF	Strong	Altered Expression	[240]
BAG4	OTUPX3M2	Strong	Altered Expression	[241]
BAHD1	OT9YGK94	Strong	Genetic Variation	[242]
BCL10	OT47MCLI	Strong	Biomarker	[243]
BCL11B	OT8KKCVJ	Strong	Genetic Variation	[244]
BCL2L11	OTNQQWFJ	Strong	Biomarker	[245]
BCL2L12	OTS6IFZY	Strong	Altered Expression	[246]
BCL2L13	OT2VRFTM	Strong	Altered Expression	[247]
BIRC6	OTCQJAB0	Strong	Biomarker	[248]
BLNK	OTSSPF6F	Strong	Biomarker	[249]
BLVRB	OTHCFN2C	Strong	Altered Expression	[147]
BMF	OT90NSLI	Strong	Biomarker	[250]
BNC1	OTGJ5WUF	Strong	Biomarker	[142]
CAPG	OTJ86KI6	Strong	Genetic Variation	[155]
CARD8	OTXXZYWU	Strong	Genetic Variation	[251]
CASD1	OT1YB54Z	Strong	Altered Expression	[252]
CASP8AP2	OTTWT68S	Strong	Biomarker	[253]
CAV2	OT1FGRQX	Strong	Biomarker	[57]
CAV3	OTWSFDB4	Strong	Altered Expression	[254]
CCNA1	OTX4HD45	Strong	Altered Expression	[255]
CD48	OT83ZNPP	Strong	Altered Expression	[193]
CD72	OTPOJID2	Strong	Genetic Variation	[256]
CDC34	OTNBK390	Strong	Altered Expression	[257]
CEACAM8	OTLL9WWO	Strong	Altered Expression	[258]
CEP72	OTVYNPNL	Strong	Genetic Variation	[259]
CERS6	OTOP4GV1	Strong	Biomarker	[260]
CFL1	OTT6D5MH	Strong	Genetic Variation	[53]
CLEC4D	OTT7X1UC	Strong	Biomarker	[261]
CLIC5	OTS315DX	Strong	Biomarker	[262]
CNDP2	OTJR9436	Strong	Genetic Variation	[263]
CNTNAP1	OT5Y03EU	Strong	Biomarker	[264]
COBL	OTTB4VFQ	Strong	Biomarker	[265]
COIL	OTP4I4DL	Strong	Biomarker	[266]
COX3	OTNNGBYJ	Strong	Genetic Variation	[238]
CREBRF	OT2GK1HI	Strong	Biomarker	[267]
CYFIP1	OTOBEH24	Strong	Biomarker	[268]
DACT1	OT19Z704	Strong	Altered Expression	[269]
DDX51	OTLMA7AH	Strong	Posttranslational Modification	[270]
DGUOK	OT78HUZB	Strong	Altered Expression	[271]
DLEU7	OTVKX1YP	Strong	Altered Expression	[272]
DLX3	OTARP5SQ	Strong	Biomarker	[273]
DSG2	OTJPB2TO	Strong	Biomarker	[274]
DUOX2	OTU14HCN	Strong	Biomarker	[275]
DUSP7	OT6Z5AHP	Strong	Altered Expression	[276]
E2F4	OTB3JFH4	Strong	Genetic Variation	[277]
EEF1E1	OTRA6XOB	Strong	Genetic Variation	[53]
EFNB1	OT7JJW8P	Strong	Biomarker	[78]
EMCN	OTS03CZC	Strong	Altered Expression	[149]
ENDOU	OTB7OF7Y	Strong	Altered Expression	[278]
ENO2	OTRODL0T	Strong	Biomarker	[279]
ERG	OTOTX9VU	Strong	Altered Expression	[280]
EVPL	OTZIAFEK	Strong	Posttranslational Modification	[264]
EXOSC6	OTAC10N6	Strong	Altered Expression	[278]
FANCB	OTMZTXB5	Strong	Biomarker	[281]
FBLIM1	OTFHXMON	Strong	Biomarker	[282]
FBLN2	OTEHR7N7	Strong	Posttranslational Modification	[142]
FBXL2	OT5EZ7PD	Strong	Altered Expression	[283]
FBXL5	OT93D50X	Strong	Biomarker	[284]
FLT3LG	OTU0YGC4	Strong	Biomarker	[285]
FMN2	OTUY7BSV	Strong	Altered Expression	[286]
FOXE3	OTAUDKC1	Strong	Posttranslational Modification	[215]
FOXO3	OTHXQG4P	Strong	Genetic Variation	[287]
GAB2	OTBFN705	Strong	Biomarker	[288]
GCFC2	OTC7FRXL	Strong	Genetic Variation	[106]
GCNT2	OTRUIMC4	Strong	Altered Expression	[86]
GLS2	OT08MSHL	Strong	Biomarker	[289]
GOPC	OTRBGH71	Strong	Biomarker	[282]
GPR19	OTR7MUS5	Strong	Biomarker	[290]
GZMA	OT43R33L	Strong	Biomarker	[291]
H2AZ1	OT3KJJNQ	Strong	Altered Expression	[292]
H2BC12	OTQ8V0KG	Strong	Altered Expression	[293]
H2BW2	OT4X4HHV	Strong	Altered Expression	[293]
HCST	OTILCB4K	Strong	Biomarker	[294]
HERPUD1	OT9EROL6	Strong	Biomarker	[135]
HFE	OTDD93KB	Strong	Genetic Variation	[295]
HLA-DRB4	OTNXIHQU	Strong	Biomarker	[296]
HLF	OTTRK9XN	Strong	Biomarker	[297]
HOXB7	OTC7WYU8	Strong	Biomarker	[298]
HOXD4	OTQR4WCG	Strong	Genetic Variation	[299]
HPR	OTXSC9UB	Strong	Biomarker	[300]
HSPA1L	OTC2V1K6	Strong	Genetic Variation	[301]
IGF2BP1	OT9G360P	Strong	Genetic Variation	[302]
IGF2BP2	OT4ZSEEE	Strong	Altered Expression	[303]
IGF2BP3	OTB97VIK	Strong	Biomarker	[303]
IKZF5	OTJN51OC	Strong	Biomarker	[304]
IL18R1	OT83XMPQ	Strong	Genetic Variation	[77]
IMPACT	OTQ923OB	Strong	Biomarker	[305]
ITPA	OTQ47WVR	Strong	Genetic Variation	[155]
KDM3B	OTZU5J5S	Strong	Altered Expression	[306]
KIDINS220	OTLBH2MA	Strong	Genetic Variation	[307]
KIR3DL1	OTPOSXFX	Strong	Genetic Variation	[85]
KIR3DS1	OTJWIO4T	Strong	Genetic Variation	[85]
KNL1	OT4Q3LHV	Strong	Biomarker	[308]
LAMTOR1	OTIBJBW9	Strong	Genetic Variation	[53]
LAT2	OTWJDKIH	Strong	Altered Expression	[309]
LBH	OT87AT1X	Strong	Altered Expression	[310]
LEF1	OTWS5I5H	Strong	Biomarker	[311]
LHX4	OTVX3J6S	Strong	Genetic Variation	[312]
LIG3	OT48SKET	Strong	Genetic Variation	[313]
MAFK	OTZJUE4P	Strong	Genetic Variation	[53]
MAP3K12	OT5HODDD	Strong	Biomarker	[147]
MBD5	OTFHT4MO	Strong	Genetic Variation	[314]
MCM2	OTGGORIQ	Strong	Altered Expression	[120]
MEIS1	OTH9DKAD	Strong	Altered Expression	[315]
METTL14	OT6TPQMH	Strong	Biomarker	[316]
METTL3	OTSXP1M3	Strong	Altered Expression	[316]
MGA	OTTLB216	Strong	Biomarker	[237]
MLLT3	OTXH4DDG	Strong	Biomarker	[317]
MOCOS	OT0TL3Q5	Strong	Biomarker	[318]
MPRIP	OT5FV5NS	Strong	Altered Expression	[39]
MRPL47	OTJ7ZJW7	Strong	Genetic Variation	[242]
MSX1	OT5U41ZP	Strong	Biomarker	[142]
MTX1	OTLSDNZO	Strong	Biomarker	[319]
NBN	OT73B5MD	Strong	Biomarker	[320]
NET1	OTZHNMJV	Strong	Altered Expression	[321]
NEU3	OTQ5PQOW	Strong	Biomarker	[322]
NOL4L	OT14W6UW	Strong	Biomarker	[239]
PARN	OTTG4PE3	Strong	Posttranslational Modification	[323]
PARP9	OT7K4494	Strong	Genetic Variation	[66]
PBX4	OTUWEWSW	Strong	Altered Expression	[315]
PCDH10	OT2GIT0E	Strong	Posttranslational Modification	[324]
PCDH17	OTRK0M05	Strong	Biomarker	[325]
PDAP1	OTJSWMOD	Strong	Biomarker	[326]
PFDN6	OTI8IPNC	Strong	Altered Expression	[327]
PHC1	OT1JMX8U	Strong	Altered Expression	[328]
PIAS2	OTJLSC3V	Strong	Biomarker	[329]
PIP4K2A	OTO9JO9U	Strong	Genetic Variation	[330]
PLA2G15	OT6VJTPA	Strong	Genetic Variation	[228]
PLEKHG2	OTMGR6I6	Strong	Biomarker	[331]
PPP1R13B	OTC88VQO	Strong	Altered Expression	[332]
PPP1R13L	OTNCPLWE	Strong	Genetic Variation	[112]
PPP2R3A	OTSK5GFC	Strong	Posttranslational Modification	[142]
PRDM9	OTWAHLUR	Strong	Genetic Variation	[333]
PRM3	OT6574BF	Strong	Genetic Variation	[334]
PRPF31	OTSJ0Z1Y	Strong	Biomarker	[335]
PSME1	OTDHLJWH	Strong	Altered Expression	[121]
PTGES3	OTPPQWI0	Strong	Altered Expression	[336]
PTPRA	OTZA82J1	Strong	Biomarker	[103]
PTPRG	OT9N2WOF	Strong	Posttranslational Modification	[337]
RAD50	OTYMU9G1	Strong	Genetic Variation	[338]
RASSF10	OTGB7EBG	Strong	Biomarker	[339]
RASSF2	OT2JHDO4	Strong	Genetic Variation	[340]
RASSF6	OT25GVWY	Strong	Biomarker	[339]
RBM19	OT3Q6UIM	Strong	Genetic Variation	[314]
RIN2	OTCY73U9	Strong	Biomarker	[109]
RMDN1	OTE1NB6U	Strong	Altered Expression	[223]
RNF213	OT4OVE9O	Strong	Genetic Variation	[341]
RRAS	OTBBF28C	Strong	Altered Expression	[336]
SEPTIN11	OTX2O0ZX	Strong	Altered Expression	[342]
SEPTIN5	OT6JTJBO	Strong	Altered Expression	[343]
SET	OTGYYQJO	Strong	Altered Expression	[344]
SETDB2	OTBVVP9Q	Strong	Biomarker	[8]
SH3GL3	OTX6BOCN	Strong	Biomarker	[138]
SHMT1	OTIINA3J	Strong	Genetic Variation	[345]
SIAE	OTDQUESH	Strong	Altered Expression	[252]
SLX4IP	OTRZQJV9	Strong	Genetic Variation	[346]
SMCP	OTXKY794	Strong	Biomarker	[318]
SMR3B	OTL5HNM8	Strong	Biomarker	[123]
SNX2	OT889MQA	Strong	Biomarker	[347]
SNX3	OTXL5W8F	Strong	Biomarker	[327]
SOAT1	OTB4Y5RJ	Strong	Biomarker	[348]
SPAG9	OT45AHMB	Strong	Genetic Variation	[349]
SRI	OT4R3EAC	Strong	Altered Expression	[350]
STAT5A	OTBSJGN3	Strong	Posttranslational Modification	[264]
STAT5B	OTZVPEBT	Strong	Posttranslational Modification	[264]
SYBU	OT3FQV7N	Strong	Altered Expression	[223]
SYNE2	OTBUXGQ0	Strong	Genetic Variation	[242]
TADA1	OTV9RKSL	Strong	Biomarker	[351]
TAL1	OTX4K6QZ	Strong	Genetic Variation	[352]
TCF7L1	OTTUTF0O	Strong	Biomarker	[353]
TCFL5	OTJL4348	Strong	Biomarker	[147]
TCIM	OTARUXQF	Strong	Genetic Variation	[354]
TCL1B	OT4CSO39	Strong	Genetic Variation	[141]
TCOF1	OT4BOYTM	Strong	Altered Expression	[355]
TEAD1	OTK6971C	Strong	Altered Expression	[356]
TFPT	OTM70AK1	Strong	Biomarker	[353]
TLE1	OT50MRZ1	Strong	Altered Expression	[357]
TLX1	OTVN0MNW	Strong	Genetic Variation	[47]
TMED10	OTUXSHH7	Strong	Altered Expression	[336]
TMEM132D	OTV6I4Z0	Strong	Biomarker	[358]
TOPORS	OT1ERFFQ	Strong	Altered Expression	[293]
TPPP2	OTI3WA6X	Strong	Genetic Variation	[53]
TSGA10	OTIF1O1T	Strong	Altered Expression	[359]
TSPAN16	OTIWCL05	Strong	Biomarker	[137]
TTC4	OTAPMYXU	Strong	Biomarker	[360]
AVEN	OTGIN5YK	Definitive	Altered Expression	[361]
CTCF	OT8ZB70U	Definitive	Posttranslational Modification	[362]
EFS	OT06O7XL	Definitive	Biomarker	[363]
EXT1	OTRPALJK	Definitive	Altered Expression	[364]
GATA2	OTBP2QQ2	Definitive	Genetic Variation	[365]
HAP1	OT6SG0JQ	Definitive	Biomarker	[366]
HLA-DRA	OT7KZMP2	Definitive	Genetic Variation	[367]
IL3	OT0CQ35N	Definitive	Genetic Variation	[83]
LMO1	OTB59SKB	Definitive	Genetic Variation	[368]
MTHFD1	OTMKHVWC	Definitive	Genetic Variation	[369]
NLRP2	OTJA81JU	Definitive	Genetic Variation	[370]
NR2E1	OTW47GKM	Definitive	Biomarker	[371]
NSD2	OTQ6SW4R	Definitive	Genetic Variation	[372]
PHF2	OTJCIQR2	Definitive	Altered Expression	[373]
RBM45	OTWTHD77	Definitive	Genetic Variation	[374]
RUNX1T1	OT30DED5	Definitive	Genetic Variation	[375]
SMARCA1	OT0Y6PTU	Definitive	Biomarker	[213]
SORL1	OTQ8FFNS	Definitive	Altered Expression	[376]
SRSF1	OTF61HOV	Definitive	Posttranslational Modification	[377]
SYNE1	OTSBSLUH	Definitive	Genetic Variation	[378]

References

• [1] Methotrexate FDA Label
• [2] Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-3505.
• [3] Prednisone FDA Label
• [4] Vincristine FDA Label
• [5] Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia.Oncotarget. 2017 Jan 31;8(5):8022-8034. doi: 10.18632/oncotarget.14038.
• [6] Absence of mutations in the CDKN2 binding site of CDK4 in childhood acute lymphoblastic leukemia.Leuk Lymphoma. 2001 Jan;40(3-4):413-7. doi: 10.3109/10428190109057941.
• [7] MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.Cell Cycle. 2014;13(5):834-44. doi: 10.4161/cc.27757.
• [8] SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.Cell Rep. 2018 Apr 24;23(4):1166-1177. doi: 10.1016/j.celrep.2018.03.124.
• [9] Variation in xenobiotic transport and metabolism genes, household chemical exposures, and risk of childhood acute lymphoblastic leukemia.Cancer Causes Control. 2012 Aug;23(8):1367-75. doi: 10.1007/s10552-012-9947-4. Epub 2012 Jun 7.
• [10] Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.Cancer Med. 2018 Apr;7(4):1297-1316. doi: 10.1002/cam4.1323. Epub 2018 Feb 23.
• [11] Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.BMC Cancer. 2016 May 26;16:335. doi: 10.1186/s12885-016-2374-2.
• [12] T cell receptor alpha-chain gene rearrangements in B-precursor leukemia are in contrast to the findings in T cell acute lymphoblastic leukemia. Comparative study of T cell receptor gene rearrangement in childhood leukemia.J Clin Invest. 1987 Dec;80(6):1770-7. doi: 10.1172/JCI113270.
• [13] CD15(+) acute lymphoblastic leukemia and subsequent monoblastic leukemia: persistence of t(4;11) abnormality and B-cell gene rearrangement.Arch Pathol Lab Med. 2001 Sep;125(9):1227-30. doi: 10.5858/2001-125-1227-CALLAS.
• [14] The role of transcription factor Sp1 in the regulation of gamma-glutamyl hydrolase gene expression by the rs3758149 polymorphism in CEM/C1 cells.Pharmazie. 2019 Nov 1;74(11):671-674. doi: 10.1691/ph.2019.9689.
• [15] HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5.
• [16] The genomic landscape of hypodiploid acute lymphoblastic leukemia.Nat Genet. 2013 Mar;45(3):242-52. doi: 10.1038/ng.2532. Epub 2013 Jan 20.
• [17] IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.
• [18] Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.Genes Chromosomes Cancer. 2005 Jan;42(1):87-94. doi: 10.1002/gcc.20116.
• [19] Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.Haematologica. 2000 Jul;85(7):711-21.
• [20] MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.JCI Insight. 2018 Nov 2;3(21):e97941. doi: 10.1172/jci.insight.97941.
• [21] Serum nm23-H1 protein as a prognostic factor in hematological malignancies.Leuk Lymphoma. 2002 Apr;43(4):859-67. doi: 10.1080/10428190290017006.
• [22] Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.J Hematol Oncol. 2017 Feb 28;10(1):61. doi: 10.1186/s13045-017-0431-1.
• [23] MicroRNA-9 suppresses cancer proliferation and cell cycle progression in acute lymphoblastic leukemia with inverse association of neuropilin-1.J Cell Biochem. 2018 Aug;119(8):6604-6613. doi: 10.1002/jcb.26799. Epub 2018 Apr 25.
• [24] The KOR-SA3544 antigen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells.Leukemia. 1999 May;13(5):779-85. doi: 10.1038/sj.leu.2401408.
• [25] Influence of genetic factors on long-term treatment related neurocognitive complications, and on anxiety and depression in survivors of childhood acute lymphoblastic leukemia: The Petale study.PLoS One. 2019 Jun 10;14(6):e0217314. doi: 10.1371/journal.pone.0217314. eCollection 2019.
• [26] Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics.Blood. 2019 Feb 14;133(7):724-729. doi: 10.1182/blood-2018-07-862946. Epub 2018 Dec 3.
• [27] CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.Int J Cancer. 2014 Aug 1;135(3):751-62. doi: 10.1002/ijc.28708. Epub 2014 Jan 13.
• [28] Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.Leuk Res. 2012 Aug;36(8):1009-15. doi: 10.1016/j.leukres.2012.04.018. Epub 2012 May 14.
• [29] Genetic variants in the folate pathway and risk of childhood acute lymphoblastic leukemia.Cancer Causes Control. 2011 Sep;22(9):1243-58. doi: 10.1007/s10552-011-9795-7. Epub 2011 Jul 12.
• [30] Spectrum and Immunophenotypic Profile of Acute Leukemia: A Tertiary Center Flow Cytometry Experience.Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019017. doi: 10.4084/MJHID.2019.017. eCollection 2019.
• [31] Association between NQO1 C609T polymorphism and acute lymphoblastic leukemia risk: evidence from an updated meta-analysis based on 17 case-control studies.J Cancer Res Clin Oncol. 2014 Jun;140(6):873-81. doi: 10.1007/s00432-014-1595-5. Epub 2014 Feb 2.
• [32] Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia.Hematology. 2013 Nov;18(6):315-22. doi: 10.1179/1607845413Y.0000000080. Epub 2013 Feb 20.
• [33] Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis.Front Immunol. 2017 Jan 5;7:666. doi: 10.3389/fimmu.2016.00666. eCollection 2016.
• [34] Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases.Asia Pac J Clin Oncol. 2015 Dec;11(4):293-8. doi: 10.1111/ajco.12400. Epub 2015 Aug 12.
• [35] Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.APMIS. 2010 May;118(5):353-9. doi: 10.1111/j.1600-0463.2010.02603.x.
• [36] Multilocus association of genetic variants in MLL, CREBBP, EP300, and TOP2A with childhood acute lymphoblastic leukemia in Hispanics from Texas.Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1204-12. doi: 10.1158/1055-9965.EPI-11-0059. Epub 2011 Apr 14.
• [37] Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.Pharmacogenomics. 2016 May;17(7):731-41. doi: 10.2217/pgs-2016-0001. Epub 2016 May 16.
• [38] Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.Pharmacogenomics J. 2018 Apr;18(2):275-280. doi: 10.1038/tpj.2017.12. Epub 2017 Apr 18.
• [39] A Bak-dependent mitochondrial amplification step contributes to Smac mimetic/glucocorticoid-induced necroptosis.Cell Death Differ. 2017 Jan;24(1):83-97. doi: 10.1038/cdd.2016.102. Epub 2016 Nov 11.
• [40] Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.MAbs. 2013 Sep-Oct;5(5):723-35. doi: 10.4161/mabs.25282. Epub 2013 Jun 7.
• [41] The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.J Oncol Pharm Pract. 2016 Feb;22(1):76-81. doi: 10.1177/1078155214553143. Epub 2014 Oct 10.
• [42] FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia.Oncol Lett. 2017 Oct;14(4):5034-5038. doi: 10.3892/ol.2017.6796. Epub 2017 Aug 23.
• [43] Deleterious and Oncogenic Mutations in the IL7RA.Cancers (Basel). 2019 Dec 5;11(12):1952. doi: 10.3390/cancers11121952.
• [44] Wnt/catenin inhibition reverses multidrug resistance in pediatric acute lymphoblastic leukemia.Oncol Rep. 2019 Feb;41(2):1387-1394. doi: 10.3892/or.2018.6902. Epub 2018 Dec 4.
• [45] Cancer immune therapy for lymphoid malignancies: recent advances.Semin Immunopathol. 2019 Jan;41(1):111-124. doi: 10.1007/s00281-018-0696-7. Epub 2018 Jul 13.
• [46] Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.Leukemia. 2017 Jul;31(7):1491-1501. doi: 10.1038/leu.2016.365. Epub 2016 Nov 30.
• [47] Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.J Hematol Oncol. 2014 Jun 2;7:43. doi: 10.1186/1756-8722-7-43.
• [48] Characterizing Iranian Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia Through Gene Expression Profiling of Common ATP Binding Cassette Transporters Subfamily C.J Pediatr Hematol Oncol. 2020 Jan;42(1):41-45. doi: 10.1097/MPH.0000000000001613.
• [49] mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value for ABCA3 and ABCA2.Cancer Biol Ther. 2014 Jan;15(1):35-41. doi: 10.4161/cbt.26603. Epub 2013 Oct 21.
• [50] Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.Leuk Res. 2019 Apr;79:45-51. doi: 10.1016/j.leukres.2019.02.008. Epub 2019 Feb 23.
• [51] Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells.Cancer Lett. 2016 May 28;375(1):127-132. doi: 10.1016/j.canlet.2016.02.040. Epub 2016 Mar 2.
• [52] AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia.Mol Cancer Ther. 2011 Mar;10(3):437-47. doi: 10.1158/1535-7163.MCT-10-0777. Epub 2011 Jan 24.
• [53] Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias.Leukemia. 1996 Feb;10(2):255-60.
• [54] Expression and prognostic significance of livin/BIRC7 in childhood acute lymphoblastic leukemia.Med Oncol. 2014 May;31(5):941. doi: 10.1007/s12032-014-0941-4. Epub 2014 Apr 3.
• [55] Expression of RUNX1 isoforms and its target gene BLK in childhood acute lymphoblastic leukemia.Leuk Res. 2012 Sep;36(9):1105-11. doi: 10.1016/j.leukres.2012.05.019. Epub 2012 Jun 29.
• [56] Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.Int J Lab Hematol. 2019 Aug;41(4):561-571. doi: 10.1111/ijlh.13052. Epub 2019 May 21.
• [57] Changes in left ventricular strain parameters following pediatric heart transplantation.Pediatr Transplant. 2018 Aug;22(5):e13166. doi: 10.1111/petr.13166. Epub 2018 Mar 25.
• [58] Silencer of death domains controls cell death through tumour necrosis factor-receptor 1 and caspase-10 in acute lymphoblastic leukemia.PLoS One. 2014 Jul 25;9(7):e103383. doi: 10.1371/journal.pone.0103383. eCollection 2014.
• [59] The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.Invest New Drugs. 2012 Apr;30(2):529-40. doi: 10.1007/s10637-010-9594-0. Epub 2010 Dec 1.
• [60] Phenotyping and Target Expression Profiling of CD34(+)/CD38(-) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15.
• [61] Should immunologic strategies be incorporated into frontline ALL therapy?.Best Pract Res Clin Haematol. 2018 Dec;31(4):367-372. doi: 10.1016/j.beha.2018.09.015. Epub 2018 Sep 25.
• [62] A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.Blood. 2010 Dec 23;116(26):5930-40. doi: 10.1182/blood-2010-01-262006. Epub 2010 Sep 15.
• [63] Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.Blood. 2001 Apr 1;97(7):2115-20. doi: 10.1182/blood.v97.7.2115.
• [64] Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.Int Immunopharmacol. 2011 Sep;11(9):1211-9. doi: 10.1016/j.intimp.2011.03.022. Epub 2011 Apr 12.
• [65] Significance of CD66c expression in childhood acute lymphoblastic leukemia.Leuk Res. 2014 Jan;38(1):42-8. doi: 10.1016/j.leukres.2013.10.008. Epub 2013 Oct 22.
• [66] Clinical and laboratory features of adult biphenotypic acute leukemia.Asia Pac J Clin Oncol. 2013 Jun;9(2):146-54. doi: 10.1111/j.1743-7563.2012.01571.x. Epub 2012 Jul 9.
• [67] Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia.Bioorg Med Chem Lett. 2018 Jun 1;28(10):1937-1942. doi: 10.1016/j.bmcl.2018.03.061. Epub 2018 Mar 23.
• [68] Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.Genome Res. 2017 Feb;27(2):185-195. doi: 10.1101/gr.209163.116. Epub 2016 Nov 30.
• [69] microRNA-146a Promotes Growth of Acute Leukemia Cells by Downregulating Ciliary Neurotrophic Factor Receptor and Activating JAK2/STAT3 Signaling.Yonsei Med J. 2019 Oct;60(10):924-934. doi: 10.3349/ymj.2019.60.10.924.
• [70] Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.Eur J Haematol. 2000 Jan;64(1):3-9. doi: 10.1034/j.1600-0609.2000.80097.x.
• [71] CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia.J Clin Oncol. 2008 Jun 20;26(18):3031-7. doi: 10.1200/JCO.2007.14.6399.
• [72] NF-kappa B mediated up-regulation of CCCTC-binding factor in pediatric acute lymphoblastic leukemia.Mol Cancer. 2014 Jan 7;13:5. doi: 10.1186/1476-4598-13-5.
• [73] Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers.Clin Cancer Res. 2001 Nov;7(11):3416-22.
• [74] Influence of variants in folate metabolism genes on 6-mercaptopurine induced toxicity during treatment for childhood acute lymphocytic leukemia.J BUON. 2019 Sep-Oct;24(5):2075-2083.
• [75] PCR-heteroduplex analysis of TCR gamma, delta and TAL-1 deletions in T-acute lymphoblastic leukemias: implications in the detection of minimal residual disease.Leuk Res. 2002 Apr;26(4):335-43. doi: 10.1016/s0145-2126(01)00130-8.
• [76] Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.Blood. 2005 Sep 1;106(5):1817-23. doi: 10.1182/blood-2004-11-4296. Epub 2005 May 17.
• [77] Rapid Capture Next-Generation Sequencing in Clinical Diagnostics of Kinase Pathway Aberrations in B-Cell Precursor ALL.Pediatr Blood Cancer. 2016 Jul;63(7):1283-6. doi: 10.1002/pbc.25975. Epub 2016 Mar 23.
• [78] Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.Blood. 2010 Mar 25;115(12):2412-9. doi: 10.1182/blood-2009-05-222208. Epub 2010 Jan 8.
• [79] GATA2 regulates the erythropoietin receptor in t(12;21) ALL.Oncotarget. 2017 Aug 2;8(39):66061-66074. doi: 10.18632/oncotarget.19792. eCollection 2017 Sep 12.
• [80] Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation.Pediatr Blood Cancer. 2018 May;65(5):e26938. doi: 10.1002/pbc.26938. Epub 2018 Jan 15.
• [81] Cardiotoxicity evaluation in pediatric patients with acute lymphoblastic leukemia - results of prospective study.Med Ultrason. 2019 Nov 24;21(4):449-455. doi: 10.11152/mu-2012.
• [82] Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells.Int J Cancer. 2004 Jan 1;108(1):78-85. doi: 10.1002/ijc.11555.
• [83] Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia.J Leukoc Biol. 2009 Mar;85(3):563-73. doi: 10.1189/jlb.0808469. Epub 2009 Jan 16.
• [84] Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis.Blood. 2004 Sep 1;104(5):1435-41. doi: 10.1182/blood-2003-12-4306. Epub 2004 May 13.
• [85] Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians.Hum Immunol. 2016 Jan;77(1):41-46. doi: 10.1016/j.humimm.2015.10.009. Epub 2015 Oct 21.
• [86] The role of interleukin-15 polymorphisms in adult acute lymphoblastic leukemia.PLoS One. 2010 Oct 25;5(10):e13626. doi: 10.1371/journal.pone.0013626.
• [87] Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.Oncotarget. 2016 Oct 4;7(40):65923-65936. doi: 10.18632/oncotarget.11688.
• [88] Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.Leuk Lymphoma. 2015;56(11):3103-8. doi: 10.3109/10428194.2015.1020802. Epub 2015 Mar 30.
• [89] Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3.Leukemia. 1991 Apr;5(4):322-31.
• [90] Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia. 2007 May;21(5):906-11. doi: 10.1038/sj.leu.2404615. Epub 2007 Mar 8.
• [91] Physcion blocks cell cycle and induces apoptosis in human B cell precursor acute lymphoblastic leukemia cells by downregulating HOXA5.Biomed Pharmacother. 2017 Oct;94:850-857. doi: 10.1016/j.biopha.2017.07.149. Epub 2017 Aug 10.
• [92] Glutathione-S-transferase polymorphism and acute lymphoblastic leukemia (ALL) in north Indian children: a case-control study and meta-analysis.J Hum Genet. 2014 Sep;59(9):529-35. doi: 10.1038/jhg.2014.66. Epub 2014 Aug 7.
• [93] Duplicated regions of AF-4 intron 4 at t(4;11) translocation breakpoints.Mol Diagn. 1999 Dec;4(4):269-83. doi: 10.1016/s1084-8592(99)80002-2.
• [94] Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia.Oncol Lett. 2017 Jan;13(1):497-505. doi: 10.3892/ol.2016.5437. Epub 2016 Nov 28.
• [95] Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.Leuk Lymphoma. 2015 May;56(5):1502-6. doi: 10.3109/10428194.2014.957204. Epub 2015 Jan 21.
• [96] KIR ligand C2 is associated with increased susceptibility to childhood ALL and confers an elevated risk for late relapse.Blood. 2014 Oct 2;124(14):2248-51. doi: 10.1182/blood-2014-05-572065. Epub 2014 Aug 27.
• [97] Association between the killer cell immunoglobulin-like receptor a haplotype and childhood acute lymphoblastic leukemia.Hum Immunol. 2017 Jul-Aug;78(7-8):510-514. doi: 10.1016/j.humimm.2017.05.002. Epub 2017 May 18.
• [98] Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report.Tumour Biol. 2014 Oct;35(10):10375-9. doi: 10.1007/s13277-014-2359-1. Epub 2014 Jul 23.
• [99] Low Expression of Leucocyte Associated Immunoglobulin Like Receptor-1 (LAIR-1/CD305) in a Cohort of Pediatric Acute Lymphoblastic Leukemia Cases.Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3131-3135. doi: 10.31557/APJCP.2018.19.11.3131.
• [100] Low Expression of miR-18a as a Characteristic of Pediatric Acute Lymphoblastic Leukemia.J Pediatr Hematol Oncol. 2017 Nov;39(8):585-588. doi: 10.1097/MPH.0000000000000921.
• [101] Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population.Pharmacogenet Genomics. 2016 Feb;26(2):100-2. doi: 10.1097/FPC.0000000000000191.
• [102] Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).Blood. 2010 Aug 12;116(6):962-70. doi: 10.1182/blood-2009-09-244673. Epub 2010 Jun 2.
• [103] Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy.Exp Mol Pathol. 2012 Feb;92(1):44-9. doi: 10.1016/j.yexmp.2011.09.004. Epub 2011 Oct 19.
• [104] Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.Kaohsiung J Med Sci. 2012 Mar;28(3):138-44. doi: 10.1016/j.kjms.2011.10.023. Epub 2012 Jan 20.
• [105] Lymphotoxin beta expression is high in chronic lymphocytic leukemia but low in small lymphocytic lymphoma: a quantitative real-time reverse transcriptase polymerase chain reaction analysis.Haematologica. 2003 Jun;88(6):654-8.
• [106] Genome-wide association study of childhood acute lymphoblastic leukemia in Korea.Leuk Res. 2010 Oct;34(10):1271-4. doi: 10.1016/j.leukres.2010.02.001. Epub 2010 Feb 26.
• [107] Acute lymphoblastic leukemia in the context of RASopathies.Eur J Med Genet. 2016 Mar;59(3):173-8. doi: 10.1016/j.ejmg.2016.01.003. Epub 2016 Feb 5.
• [108] Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.Cancer Res. 2001 Aug 1;61(15):5803-9.
• [109] Tenovin-6-mediated inhibition of SIRT1/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem/progenitor cells.BMC Cancer. 2015 Apr 7;15:226. doi: 10.1186/s12885-015-1282-1.
• [110] Reduced Neutrophil Elastase Activity and Neutrophil Extracellular Traps in Pediatric Acute Myeloid Leukemia May Increase the Rate of Infections.J Pediatr Hematol Oncol. 2018 May;40(4):e248-e252. doi: 10.1097/MPH.0000000000001015.
• [111] Prognostic significance of the Musashi-2 (MSI2) gene in childhood acute lymphoblastic leukemia.Neoplasma. 2016;63(1):150-7. doi: 10.4149/neo_2016_018.
• [112] Focused screening of a panel of cancer-related genetic polymorphisms reveals new susceptibility loci for pediatric acute lymphoblastic leukemia.Pediatr Blood Cancer. 2014 Aug;61(8):1411-5. doi: 10.1002/pbc.25011. Epub 2014 Mar 6.
• [113] Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.Asian Pac J Cancer Prev. 2014;15(22):9961-6. doi: 10.7314/apjcp.2014.15.22.9961.
• [114] Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.Oncotarget. 2017 Dec 31;9(5):5529-5544. doi: 10.18632/oncotarget.23797. eCollection 2018 Jan 19.
• [115] The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.Int J Cancer. 2018 Apr 1;142(7):1490-1502. doi: 10.1002/ijc.31170. Epub 2017 Dec 26.
• [116] Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.Clin Epigenetics. 2018 Jun 19;10:83. doi: 10.1186/s13148-018-0516-x. eCollection 2018.
• [117] Pneumatosis cystoides intestinalis with abdominal free air in a 2-year-old girl after allogeneic bone marrow transplantation.Pediatr Hematol Oncol. 1998 Jan-Feb;15(1):81-4. doi: 10.3109/08880019809009512.
• [118] Expression of PIM-2 and NF-B genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.Postepy Hig Med Dosw (Online). 2013 Jun 7;67:553-9. doi: 10.5604/17322693.1052449.
• [119] Sgc8 aptamer targeted glutathione-responsive nanoassemblies containing Ara-C prodrug for the treatment of acute lymphoblastic leukemia.Nanoscale. 2019 Dec 21;11(47):23000-23012. doi: 10.1039/c9nr07391d. Epub 2019 Nov 26.
• [120] Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia.Medicine (Baltimore). 2018 May;97(20):e10734. doi: 10.1097/MD.0000000000010734.
• [121] Differential expression pattern of protein markers for predicting chemosensitivity of dexamethasone-based chemotherapy of B cell acute lymphoblastic leukemia.Cancer Chemother Pharmacol. 2017 Jul;80(1):177-185. doi: 10.1007/s00280-017-3347-0. Epub 2017 Jun 5.
• [122] Characterization of the specific interaction between the DNA aptamer sgc8c and protein tyrosine kinase-7 receptors at the surface of T-cells by biosensing AFM.Anal Bioanal Chem. 2017 Apr;409(11):2767-2776. doi: 10.1007/s00216-017-0238-5. Epub 2017 Feb 22.
• [123] Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance.Oncotarget. 2017 Dec 13;9(3):3549-3561. doi: 10.18632/oncotarget.23186. eCollection 2018 Jan 9.
• [124] Aberrant DNA methylation of key genes and Acute Lymphoblastic Leukemia.Biomed Pharmacother. 2018 Jan;97:1493-1500. doi: 10.1016/j.biopha.2017.11.033. Epub 2017 Nov 20.
• [125] Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.Curr Oncol Rep. 2018 Apr 30;20(7):52. doi: 10.1007/s11912-018-0696-8.
• [126] Germline configuration of nfkb2, c-rel and bcl3 in childhood acute lymphoblastic leukemia (ALL).Leukemia. 1997 Aug;11(8):1364-6. doi: 10.1038/sj.leu.2400778.
• [127] Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.Leuk Lymphoma. 2013 Apr;54(4):843-50. doi: 10.3109/10428194.2012.731599. Epub 2012 Oct 9.
• [128] p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation.Leukemia. 1999 Jun;13(6):884-90. doi: 10.1038/sj.leu.2401437.
• [129] Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.Blood Adv. 2019 Oct 22;3(20):3143-3156. doi: 10.1182/bloodadvances.2019000051.
• [130] Examination of HFE associations with childhood leukemia risk and extension to other iron regulatory genes.Leuk Res. 2014 Sep;38(9):1055-60. doi: 10.1016/j.leukres.2014.06.016. Epub 2014 Jul 11.
• [131] Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.BMC Genomics. 2009 Dec 23;10:625. doi: 10.1186/1471-2164-10-625.
• [132] Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.Pediatr Blood Cancer. 2015 Apr;62(4):622-8. doi: 10.1002/pbc.25379. Epub 2015 Jan 3.
• [133] Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.Leuk Res. 2018 Feb;65:61-66. doi: 10.1016/j.leukres.2018.01.004. Epub 2018 Jan 2.
• [134] SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor.Leuk Res. 2014 Apr;38(4):496-502. doi: 10.1016/j.leukres.2014.01.013. Epub 2014 Feb 5.
• [135] Long non-coding RNA SNHG16 has Tumor suppressing effect in acute lymphoblastic leukemia by inverse interaction on hsa-miR-124-3p.IUBMB Life. 2019 Jan;71(1):134-142. doi: 10.1002/iub.1947. Epub 2018 Oct 31.
• [136] Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression.Cancer Res. 2014 May 15;74(10):2803-15. doi: 10.1158/0008-5472.CAN-13-2732. Epub 2014 Mar 31.
• [137] Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.J Clin Oncol. 2007 Apr 10;25(11):1341-9. doi: 10.1200/JCO.2006.09.3534. Epub 2007 Feb 20.
• [138] Maternal Red Blood Cell Folate and Infant Vitamin B(12) Status Influence Methylation of Genes Associated with Childhood Acute Lymphoblastic Leukemia.Mol Nutr Food Res. 2018 Nov;62(22):e1800411. doi: 10.1002/mnfr.201800411. Epub 2018 Oct 11.
• [139] SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia Patients.Int J Mol Sci. 2019 Dec 7;20(24):6175. doi: 10.3390/ijms20246175.
• [140] The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1.Genes Chromosomes Cancer. 2008 Dec;47(12):1118-25. doi: 10.1002/gcc.20613.
• [141] IGH gene involvement in two cases of acute lymphoblastic leukemia with t(14;14)(q11;q32) identified by sequential R-banding and fluorescence in situ hybridization.Cancer Genet Cytogenet. 2004 Jul 15;152(2):141-5. doi: 10.1016/j.cancergencyto.2003.11.008.
• [142] Epigenetic analysis of childhood acute lymphoblastic leukemia.Epigenetics. 2009 Apr 1;4(3):185-93. doi: 10.4161/epi.4.3.8752. Epub 2009 Apr 12.
• [143] Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease.Leukemia. 2012 Jun;26(6):1203-10. doi: 10.1038/leu.2011.341. Epub 2011 Dec 2.
• [144] CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia.Leukemia. 2012 Aug;26(8):1797-803. doi: 10.1038/leu.2012.60. Epub 2012 Mar 5.
• [145] CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.Sci Transl Med. 2019 Sep 25;11(511):eaaw9414. doi: 10.1126/scitranslmed.aaw9414.
• [146] Novel cryptic chromosomal rearrangements in childhood acute lymphoblastic leukemia detected by multiple color fluorescent in situ hybridization.Haematologica. 2005 Sep;90(9):1179-85.
• [147] Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia.Leuk Lymphoma. 2013 Feb;54(2):310-4. doi: 10.3109/10428194.2012.710330. Epub 2012 Sep 8.
• [148] Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).Blood. 2015 Jan 29;125(5):820-30. doi: 10.1182/blood-2014-06-583062. Epub 2014 Nov 26.
• [149] A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia.Haematologica. 2005 Jul;90(7):890-8.
• [150] Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation.BMC Cancer. 2012 Feb 7;12:60. doi: 10.1186/1471-2407-12-60.
• [151] Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia.Integr Biol (Camb). 2016 Jul 11;8(7):761-74. doi: 10.1039/c6ib00040a. Epub 2016 Jun 17.
• [152] ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.Blood. 2006 Jan 1;107(1):197-204. doi: 10.1182/blood-2005-04-1755. Epub 2005 Sep 13.
• [153] Viral infection-oxidative stress/DNA damage-aberrant DNA methylation: separate or interrelated events responsible for genetic instability and childhood ALL development?.Biochim Biophys Acta. 2014 Aug;1846(1):226-31. doi: 10.1016/j.bbcan.2014.06.004. Epub 2014 Jul 5.
• [154] Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.Anticancer Res. 2019 Oct;39(10):5531-5539. doi: 10.21873/anticanres.13746.
• [155] Classification and regression tree-based prediction of 6-mercaptopurine-induced leucopenia grades in children with acute lymphoblastic leukemia.Cancer Chemother Pharmacol. 2019 May;83(5):875-880. doi: 10.1007/s00280-019-03803-8. Epub 2019 Feb 26.
• [156] DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia.Leuk Res. 2010 Oct;34(10):1275-81. doi: 10.1016/j.leukres.2010.02.035. Epub 2010 Apr 14.
• [157] Letter regarding Zhao et al. entitled " DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia".Tumour Biol. 2017 Jun;39(6):1010428317701629. doi: 10.1177/1010428317701629.
• [158] Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.ACS Med Chem Lett. 2019 Sep 19;10(10):1498-1503. doi: 10.1021/acsmedchemlett.9b00400. eCollection 2019 Oct 10.
• [159] Aberrant EPHB4 gene methylation and childhood acute lymphoblastic leukemia.Oncol Lett. 2017 Oct;14(4):4433-4440. doi: 10.3892/ol.2017.6755. Epub 2017 Aug 16.
• [160] The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.Leuk Res. 2013 Oct;37(10):1200-7. doi: 10.1016/j.leukres.2013.07.016. Epub 2013 Aug 12.
• [161] IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.Cancer Lett. 2019 Aug 1;456:59-68. doi: 10.1016/j.canlet.2019.04.030. Epub 2019 Apr 28.
• [162] Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study.Biol Blood Marrow Transplant. 2020 Mar;26(3):431-437. doi: 10.1016/j.bbmt.2019.10.032. Epub 2019 Nov 6.
• [163] A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia.Leuk Res. 2011 Aug;35(8):1052-9. doi: 10.1016/j.leukres.2011.02.020. Epub 2011 Mar 16.
• [164] PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy.Leuk Res. 2017 Jan;52:43-49. doi: 10.1016/j.leukres.2016.11.005. Epub 2016 Nov 11.
• [165] Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies.BMC Med Genomics. 2010 Mar 8;3:6. doi: 10.1186/1755-8794-3-6.
• [166] Antithrombin III as the Indicator of L-Asparaginase Activity in Children Treated for Acute Lymphoblastic Leukemia.J Pediatr Hematol Oncol. 2017 Mar;39(2):114-120. doi: 10.1097/MPH.0000000000000739.
• [167] Clinical significance of the TNF- receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia.Cytokine. 2018 Nov;111:523-529. doi: 10.1016/j.cyto.2018.05.025. Epub 2018 Jun 1.
• [168] Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway.Oncol Lett. 2018 Oct;16(4):5473-5481. doi: 10.3892/ol.2018.9291. Epub 2018 Aug 10.
• [169] The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.Clin Cancer Res. 2017 May 15;23(10):2528-2541. doi: 10.1158/1078-0432.CCR-16-1580. Epub 2016 Oct 25.
• [170] Dysregulation of miR-335-3p, targeted by NEAT1 and MALAT1 long non-coding RNAs, is associated with poor prognosis in childhood acute lymphoblastic leukemia.Gene. 2019 Apr 15;692:35-43. doi: 10.1016/j.gene.2019.01.003. Epub 2019 Jan 11.
• [171] Improving risk stratification of patients with childhood acute lymphoblastic leukemia: Glutathione-S-Transferases polymorphisms are associated with increased risk of relapse.Oncotarget. 2017 Jan 3;8(1):110-117. doi: 10.18632/oncotarget.8606.
• [172] Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.Pharmacogenomics J. 2016 Nov;16(6):530-535. doi: 10.1038/tpj.2015.63. Epub 2015 Sep 8.
• [173] Expression of ABCB5 gene in hematological malignances and its significance.Leuk Lymphoma. 2012 Jun;53(6):1211-5. doi: 10.3109/10428194.2011.637214. Epub 2011 Dec 7.
• [174] Congenital chloride losing diarrhea: A single center experience in a highly consanguineous population.Medicine (Baltimore). 2019 May;98(22):e15928. doi: 10.1097/MD.0000000000015928.
• [175] Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.BMC Cancer. 2018 Jul 3;18(1):704. doi: 10.1186/s12885-018-4629-6.
• [176] Ginger extract has anti-leukemia and anti-drug resistant effects on malignant cells.J Cancer Res Clin Oncol. 2019 Aug;145(8):1987-1998. doi: 10.1007/s00432-019-02949-5. Epub 2019 Jun 18.
• [177] Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome.Rev Environ Health. 2001 Jul-Sep;16(4):263-79. doi: 10.1515/reveh.2001.16.4.263.
• [178] Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia.Arch Toxicol. 2012 Mar;86(3):431-9. doi: 10.1007/s00204-011-0760-8. Epub 2011 Oct 9.
• [179] Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation.Leukemia. 2010 Oct;24(10):1742-50. doi: 10.1038/leu.2010.174. Epub 2010 Aug 12.
• [180] V(D)J recombinase-mediated HPRT mutations in peripheral blood lymphocytes of normal children.Cancer Res. 1996 Mar 15;56(6):1405-12.
• [181] Methylation of the promoter region of the MTRR gene in childhood acute lymphoblastic leukemia.Oncol Rep. 2019 Jun;41(6):3488-3498. doi: 10.3892/or.2019.7114. Epub 2019 Apr 12.
• [182] Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia.Blood. 2009 Mar 5;113(10):2284-9. doi: 10.1182/blood-2008-07-165928. Epub 2008 Nov 19.
• [183] The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia.Blood. 1995 Oct 15;86(8):3173-80.
• [184] Mutation Screening and Association Study of the Folylpolyglutamate Synthetase (FPGS) Gene with Susceptibility to Childhood Acute Lymphoblastic Leukemia.Asian Pac J Cancer Prev. 2015;16(11):4727-32. doi: 10.7314/apjcp.2015.16.11.4727.
• [185] Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.Blood. 2020 Jan 2;135(1):41-55. doi: 10.1182/blood.2019002220.
• [186] Multidrug resistance in acute leukemia: a comparison of different diagnostic methods.Leukemia. 1997 Jul;11(7):1067-72. doi: 10.1038/sj.leu.2400691.
• [187] Simultaneous involvement of 11q23 translocation resulting in chimeric MLL-AFF1 and a second translocation [t (9;21) (p13; p11.2)] in an infant acute lymphoblastic leukemia patient at relapse: A case report.Medicine (Baltimore). 2018 May;97(21):e10874. doi: 10.1097/MD.0000000000010874.
• [188] LAF-4 is aberrantly expressed in human breast cancer.Int J Cancer. 2005 Jul 1;115(4):568-74. doi: 10.1002/ijc.20881.
• [189] ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia.Clin Cancer Res. 2020 Jan 1;26(1):256-264. doi: 10.1158/1078-0432.CCR-19-0190. Epub 2019 Oct 1.
• [190] MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.J Clin Oncol. 2016 Oct 1;34(28):3451-9. doi: 10.1200/JCO.2016.66.5547. Epub 2016 Aug 9.
• [191] The novel CALM interactor CATS influences the subcellular localization of the leukemogenic fusion protein CALM/AF10.Oncogene. 2006 Jul 6;25(29):4099-109. doi: 10.1038/sj.onc.1209438. Epub 2006 Feb 20.
• [192] Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF interaction.Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14592-7. doi: 10.1073/pnas.1200037109. Epub 2012 Aug 21.
• [193] Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage.Arch Pathol Lab Med. 2003 Mar;127(3):356-9. doi: 10.5858/2003-127-0356-BALWCO.
• [194] Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.Blood. 2019 Oct 10;134(15):1227-1237. doi: 10.1182/blood.2018890764.
• [195] ckshs expression is linked to cell proliferation in normal and malignant human lymphoid cells.Int J Cancer. 1999 Jul 2;82(1):98-104. doi: 10.1002/(sici)1097-0215(19990702)82:1<98::aid-ijc17>3.0.co;2-a.
• [196] Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias.Am J Hematol. 2005 Dec;80(4):282-7. doi: 10.1002/ajh.20503.
• [197] STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.Blood. 1996 Mar 1;87(5):1692-7.
• [198] Transcriptional regulation of the human reduced folate carrier in childhood acute lymphoblastic leukemia cells.Clin Cancer Res. 2006 Jan 15;12(2):608-16. doi: 10.1158/1078-0432.CCR-05-1954.
• [199] The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype.Blood. 2003 Dec 15;102(13):4493-8. doi: 10.1182/blood-2002-11-3461. Epub 2003 Jun 19.
• [200] Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.Sao Paulo Med J. 2004 Jul 1;122(4):166-71. doi: 10.1590/s1516-31802004000400007. Epub 2004 Nov 9.
• [201] Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.Hum Gene Ther. 2018 May;29(5):602-613. doi: 10.1089/hum.2017.207. Epub 2018 Apr 16.
• [202] Acute leukemia with PICALM-MLLT10 fusion gene: diagnostic and treatment struggle.Cancer Genet Cytogenet. 2010 Oct 15;202(2):129-32. doi: 10.1016/j.cancergencyto.2010.07.126.
• [203] Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.
• [204] Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.Int J Lab Hematol. 2008 Aug;30(4):286-91. doi: 10.1111/j.1751-553X.2007.00954.x.
• [205] The nuclear migration gene NudC and human hematopoiesis.Leuk Lymphoma. 2000 Nov;39(5-6):447-54. doi: 10.3109/10428190009113375.
• [206] PACSIN2 rs2413739 influence on thiopurine pharmacokinetics: validation studies in pediatric patients.Pharmacogenomics J. 2020 Jun;20(3):415-425. doi: 10.1038/s41397-019-0130-0. Epub 2019 Dec 3.
• [207] Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.Oncogene. 2014 Apr 24;33(17):2169-78. doi: 10.1038/onc.2013.169. Epub 2013 Jun 3.
• [208] Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction.Cancer Res. 2001 Mar 15;61(6):2517-22.
• [209] The zinc finger SET domain gene Prdm14 is overexpressed in lymphoblastic lymphomas with retroviral insertions at Evi32.PLoS One. 2008;3(11):e3823. doi: 10.1371/journal.pone.0003823. Epub 2008 Nov 27.
• [210] The ARTS connection: role of ARTS in apoptosis and cancer.Cell Cycle. 2004 Aug;3(8):1021-3. Epub 2004 Aug 16.
• [211] Hypomethylated status, but not RAG-1, is required for T-cell receptor-beta-chain gene rearrangement in acute leukemia cells.Cancer Genet Cytogenet. 1994 Nov;78(1):40-5. doi: 10.1016/0165-4608(94)90044-2.
• [212] Prognostic significance of copy number alterations detected by multi-link probe amplification of multiple genes in adult acute lymphoblastic leukemia.Oncol Lett. 2018 Apr;15(4):5359-5367. doi: 10.3892/ol.2018.7985. Epub 2018 Feb 7.
• [213] SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.Nat Genet. 2017 Feb;49(2):289-295. doi: 10.1038/ng.3746. Epub 2016 Dec 12.
• [214] Analysis of HFE and TFR2 gene mutations in patients with acute leukemia.Leuk Res. 2005 Jun;29(6):661-4. doi: 10.1016/j.leukres.2005.01.001. Epub 2005 Feb 12.
• [215] Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia.Clin Chem. 2014 Jul;60(7):995-1003. doi: 10.1373/clinchem.2013.219956. Epub 2014 May 14.
• [216] Aberrant expression of the homeobox gene CDX2 in pediatric acute lymphoblastic leukemia.Blood. 2009 Apr 23;113(17):4049-51. doi: 10.1182/blood-2008-12-196634. Epub 2009 Feb 13.
• [217] Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.Blood. 2015 Jul 2;126(1):69-75. doi: 10.1182/blood-2015-02-628800. Epub 2015 May 18.
• [218] Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia.Cancer Cell. 2013 Feb 11;23(2):200-14. doi: 10.1016/j.ccr.2013.01.011.
• [219] Differences in meiotic recombination rates in childhood acute lymphoblastic leukemia at an MHC class II hotspot close to disease associated haplotypes.PLoS One. 2014 Jun 24;9(6):e100480. doi: 10.1371/journal.pone.0100480. eCollection 2014.
• [220] AAV8 vector expressing IL24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice.Blood. 2012 Jan 5;119(1):64-71. doi: 10.1182/blood-2011-05-354050. Epub 2011 Oct 24.
• [221] Prognostic impact of p15 gene aberrations in acute leukemia.Leuk Lymphoma. 2017 Feb;58(2):257-265. doi: 10.1080/10428194.2016.1201574. Epub 2016 Jul 12.
• [222] Mutations of perforin gene in Chinese patients with acute lymphoblastic leukemia.Leuk Res. 2011 Feb;35(2):196-9. doi: 10.1016/j.leukres.2010.06.016. Epub 2010 Jul 16.
• [223] Beclin-1 and hypoxia-inducible factor-1 genes expression: Potential biomarkers in acute leukemia patients.Cancer Biomark. 2016 Mar 18;16(4):619-26. doi: 10.3233/CBM-160603.
• [224] Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma.Pediatr Hematol Oncol. 2010 Aug;27(5):344-54. doi: 10.3109/08880011003739422.
• [225] Human Adipose Tissue Stem Cells Promote the Growth of Acute Lymphoblastic Leukemia Cells in NOD/SCID Mice.Stem Cell Rev Rep. 2018 Jun;14(3):451-460. doi: 10.1007/s12015-018-9806-0.
• [226] The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.J Pediatr. 2020 Jan;216:150-157.e1. doi: 10.1016/j.jpeds.2019.09.024. Epub 2019 Oct 18.
• [227] The role of p73 in hematological malignancies.Leukemia. 2006 May;20(5):757-66. doi: 10.1038/sj.leu.2404166.
• [228] Development of Escherichia coli Asparaginase II for Immunosensing: A Trade-Off between Receptor Density and Sensing Efficiency.ACS Omega. 2017 May 31;2(5):2114-2125. doi: 10.1021/acsomega.7b00110. Epub 2017 May 17.
• [229] Recent advances in childhood vasculitis.Curr Opin Rheumatol. 2017 Sep;29(5):530-534. doi: 10.1097/BOR.0000000000000424.
• [230] ADAMTSL5 and CDH11: putative epigenetic markers for therapeutic resistance in acute lymphoblastic leukemia.Hematology. 2017 Aug;22(7):386-391. doi: 10.1080/10245332.2017.1299417. Epub 2017 Mar 15.
• [231] Attenuating the abnormally high expression of AEBP1 suppresses the pathogenesis of childhood acute lymphoblastic leukemia via p53-dependent signaling pathway.Eur Rev Med Pharmacol Sci. 2019 Feb;23(3):1184-1195. doi: 10.26355/eurrev_201902_17011.
• [232] Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23).Oncogene. 2003 May 8;22(18):2851-5. doi: 10.1038/sj.onc.1206389.
• [233] Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.Genes Chromosomes Cancer. 2018 Sep;57(9):471-477. doi: 10.1002/gcc.6. Epub 2018 Jul 30.
• [234] Genome-wide identification of microRNA signatures associated with stem/progenitor cells in Philadelphia chromosome-positive acute lymphoblastic leukemia.Mol Biol Rep. 2019 Feb;46(1):1295-1306. doi: 10.1007/s11033-019-04600-5. Epub 2019 Feb 2.
• [235] ETV6/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype.Genes Chromosomes Cancer. 2017 Aug;56(8):608-616. doi: 10.1002/gcc.22464. Epub 2017 May 5.
• [236] ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.Blood. 2011 Nov 24;118(22):5883-90. doi: 10.1182/blood-2011-05-355560. Epub 2011 Oct 4.
• [237] RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.Nat Genet. 2014 Feb;46(2):116-25. doi: 10.1038/ng.2874. Epub 2014 Jan 12.
• [238] Novel non-neutral mitochondrial DNA mutations found in childhood acute lymphoblastic leukemia.Clin Genet. 2018 Feb;93(2):275-285. doi: 10.1111/cge.13100. Epub 2017 Dec 20.
• [239] Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray.Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11921-6. doi: 10.1073/pnas.0711039105. Epub 2008 Aug 12.
• [240] Evaluation of rs62527607 [GT] single nucleotide polymorphism located in BAALC gene in children with acute leukemia using mismatch PCR-RFLP.Cancer Genet. 2016 Jul-Aug;209(7-8):348-53. doi: 10.1016/j.cancergen.2016.06.005. Epub 2016 Jun 16.
• [241] Significance of SODD expression in childhood acute lymphoblastic leukemia and its influence on chemotherapy.Genet Mol Res. 2014 Mar 24;13(1):2020-31. doi: 10.4238/2014.March.24.6.
• [242] Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing.Pharmacogenomics. 2018 Oct;19(15):1181-1193. doi: 10.2217/pgs-2018-0093. Epub 2018 Sep 7.
• [243] The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010 Mar;77(3):483-94. doi: 10.1124/mol.109.060780. Epub 2009 Dec 28.
• [244] The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2).Cancer Res. 2003 Sep 1;63(17):5329-34.
• [245] Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia.Pharmacogenomics J. 2019 Feb;19(1):33-41. doi: 10.1038/s41397-017-0002-4. Epub 2017 Dec 27.
• [246] BCL2L12 improves risk stratification and prediction of BFM-chemotherapy response in childhood acute lymphoblastic leukemia.Clin Chem Lab Med. 2018 Nov 27;56(12):2104-2118. doi: 10.1515/cclm-2018-0507.
• [247] Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia.Leuk Res. 2010 Jan;34(1):18-23. doi: 10.1016/j.leukres.2009.07.023.
• [248] BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis.Eur J Haematol. 2012 Feb;88(2):118-27. doi: 10.1111/j.1600-0609.2011.01734.x. Epub 2012 Jan 4.
• [249] Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia.Leukemia. 2004 May;18(5):922-5. doi: 10.1038/sj.leu.2403349.
• [250] Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response.Pediatr Blood Cancer. 2009 Dec;53(6):984-91. doi: 10.1002/pbc.22163.
• [251] Investigation of NF-B-94ins/del ATTG and CARD8 (rs2043211) Gene Polymorphism in Acute Lymphoblastic Leukemia.Front Endocrinol (Lausanne). 2019 Aug 2;10:501. doi: 10.3389/fendo.2019.00501. eCollection 2019.
• [252] Regulation of O-acetylation of sialic acids by sialate-O-acetyltransferase and sialate-O-acetylesterase activities in childhood acute lymphoblastic leukemia.Glycobiology. 2012 Jan;22(1):70-83. doi: 10.1093/glycob/cwr106. Epub 2011 Jul 29.
• [253] Transcription factor E2F3a regulates CASP8AP2 transcription and enhances sensitivity to chemotherapeutic drugs in acute lymphoblastic leukemia.Cancer Cell Int. 2018 Mar 20;18:40. doi: 10.1186/s12935-018-0531-1. eCollection 2018.
• [254] Deletion of 6q16-q21 in human lymphoid malignancies: a mapping and deletion analysis.Cancer Res. 2000 Jun 1;60(11):2775-9.
• [255] WT1 regulates cyclinA1 expression in K562cells.Oncol Rep. 2019 Nov;42(5):2016-2028. doi: 10.3892/or.2019.7287. Epub 2019 Aug 21.
• [256] G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.Blood. 1992 Dec 1;80(11):2826-34.
• [257] Expression and localization of the CDC34 ubiquitin-conjugating enzyme in pediatric acute lymphoblastic leukemia.Cell Growth Differ. 2001 Aug;12(8):427-33.
• [258] High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias.Ann Hematol. 2008 Mar;87(3):205-11. doi: 10.1007/s00277-007-0388-1. Epub 2007 Oct 2.
• [259] Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment.Genes (Basel). 2019 Mar 1;10(3):191. doi: 10.3390/genes10030191.
• [260] Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia.Cell Death Dis. 2018 Sep 11;9(9):925. doi: 10.1038/s41419-018-0964-4.
• [261] The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype.Leuk Res. 2003 Mar;27(3):231-4. doi: 10.1016/s0145-2126(02)00129-7.
• [262] CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia.Haematologica. 2016 Dec;101(12):1534-1543. doi: 10.3324/haematol.2016.149740. Epub 2016 Aug 18.
• [263] Oligomeric interface modulation causes misregulation of purine 5-nucleotidase in relapsed leukemia.BMC Biol. 2016 Oct 19;14(1):91. doi: 10.1186/s12915-016-0313-y.
• [264] Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.Leuk Res. 2019 Apr;79:6-16. doi: 10.1016/j.leukres.2019.01.012. Epub 2019 Jan 24.
• [265] COBL is a novel hotspot for IKZF1 deletions in childhood acute lymphoblastic leukemia.Oncotarget. 2016 Aug 16;7(33):53064-53073. doi: 10.18632/oncotarget.10590.
• [266] The prognostic potential of coilin in association with p27 expression in pediatric acute lymphoblastic leukemia for disease relapse.Cancer Cell Int. 2018 Jul 27;18:106. doi: 10.1186/s12935-018-0600-5. eCollection 2018.
• [267] Monosomy 20 as a pointer to dicentric (9;20) in acute lymphoblastic leukemia.Leukemia. 2000 Feb;14(2):241-6. doi: 10.1038/sj.leu.2401654.
• [268] Cyfip1 is downregulated in acute lymphoblastic leukemia and may be a potential biomarker in acute lymphoblastic leukemia.Tumour Biol. 2016 Jul;37(7):9285-8. doi: 10.1007/s13277-016-4786-7. Epub 2016 Jan 15.
• [269] Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia.Blood. 2007 Apr 15;109(8):3462-9. doi: 10.1182/blood-2006-09-047043. Epub 2006 Dec 5.
• [270] Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 2007 Mar 15;67(6):2617-25.
• [271] Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5'-nucleotidase mRNA measurement in cell lines and in patients with leukemia.Leukemia. 2002 Mar;16(3):386-92. doi: 10.1038/sj.leu.2402388.
• [272] T-cell acute lymphoblastic leukemia with natural killer cell phenotype.Am J Hematol. 1986 Aug;22(4):355-64. doi: 10.1002/ajh.2830220404.
• [273] Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation.Oncol Rep. 2007 Aug;18(2):417-23.
• [274] Disturbed Desmoglein-2 in the intercalated disc of pediatric patients with dilated cardiomyopathy.Hum Pathol. 2017 Sep;67:101-108. doi: 10.1016/j.humpath.2017.07.012. Epub 2017 Jul 29.
• [275] Identification of genetic variants associated with skeletal muscle function deficit in childhood acute lymphoblastic leukemia survivors.Pharmgenomics Pers Med. 2019 Apr 11;12:33-45. doi: 10.2147/PGPM.S192924. eCollection 2019.
• [276] Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells.Oncogene. 2003 Oct 23;22(48):7649-60. doi: 10.1038/sj.onc.1206971.
• [277] Mutations of the E2F4 gene in hematological malignancies having microsatellite instability.Blood. 2000 Feb 15;95(4):1509-10.
• [278] Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy.PLoS One. 2015 Oct 14;10(10):e0140564. doi: 10.1371/journal.pone.0140564. eCollection 2015.
• [279] ENO2 Promotes Cell Proliferation, Glycolysis, and Glucocorticoid-Resistance in Acute Lymphoblastic Leukemia.Cell Physiol Biochem. 2018;46(4):1525-1535. doi: 10.1159/000489196. Epub 2018 Apr 19.
• [280] Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.Nat Genet. 2016 Dec;48(12):1481-1489. doi: 10.1038/ng.3691. Epub 2016 Oct 24.
• [281] Current status of diagnosis and prognosis of infant acute leukemia in China.Pediatr Blood Cancer. 2009 Dec;53(6):973-7. doi: 10.1002/pbc.22145.
• [282] PI3K- inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.Anticancer Drugs. 2017 Apr;28(4):436-445. doi: 10.1097/CAD.0000000000000477.
• [283] F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation.Blood. 2012 Mar 29;119(13):3132-41. doi: 10.1182/blood-2011-06-358911. Epub 2012 Feb 8.
• [284] Identification of promising prognostic genes for relapsed acute lymphoblastic leukemia.Blood Cells Mol Dis. 2019 Jul;77:113-119. doi: 10.1016/j.bcmd.2019.04.010. Epub 2019 Apr 18.
• [285] Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.Leuk Res. 2018 Dec;75:36-44. doi: 10.1016/j.leukres.2018.11.001. Epub 2018 Nov 3.
• [286] MicroRNA-144 regulates cancer cell proliferation and cell-cycle transition in acute lymphoblastic leukemia through the interaction of FMN2.J Gene Med. 2017 Jun;19(6-7). doi: 10.1002/jgm.2898.
• [287] FOXO3 gene polymorphisms influence the risk of acute lymphoblastic leukemia in Chinese children.J Cell Biochem. 2020 Feb;121(2):2019-2026. doi: 10.1002/jcb.29436. Epub 2019 Nov 6.
• [288] Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.Genes Chromosomes Cancer. 2019 Oct;58(10):723-730. doi: 10.1002/gcc.22765. Epub 2019 May 27.
• [289] A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo.Cancer Res. 2018 Mar 15;78(6):1549-1560. doi: 10.1158/0008-5472.CAN-17-2106. Epub 2018 Jan 17.
• [290] Physical mapping of the G-protein coupled receptor 19 (GPR19) in the chromosome 12p12.3 region frequently rearranged in cancer cells.Hum Genet. 1999 Jul-Aug;105(1-2):162-4. doi: 10.1007/s004399900083.
• [291] Glucocorticoid-induced granzyme A expression can be used as a marker of glucocorticoid sensitivity for acute lymphoblastic leukemia therapy.J Hum Genet. 2007;52(4):328-333. doi: 10.1007/s10038-007-0119-4. Epub 2007 Feb 20.
• [292] Significance of CASP8AP2 and H2AFZ expression in survival and risk of relapse in children with acute lymphoblastic leukemia.Leuk Lymphoma. 2014 Oct;55(10):2305-11. doi: 10.3109/10428194.2013.878458. Epub 2014 Feb 24.
• [293] Novel potential ALL low-risk markers revealed by gene expression profiling with new high-throughput SSH-CCS-PCR.Leukemia. 2003 Sep;17(9):1891-900. doi: 10.1038/sj.leu.2403073.
• [294] Motor skill delays in pre-school children with leukemia one year after treatment: Hematopoietic stem cell transplantation therapy as an important risk factor.PLoS One. 2017 Oct 24;12(10):e0186787. doi: 10.1371/journal.pone.0186787. eCollection 2017.
• [295] HFE gene mutation and iron overload in Egyptian pediatric acute lymphoblastic leukemia survivors: a single-center study.Hematology. 2017 Aug;22(7):398-404. doi: 10.1080/10245332.2017.1289324. Epub 2017 Feb 17.
• [296] Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia.Blood. 1999 Jul 15;94(2):694-700.
• [297] NGS-based methylation profiling differentiates TCF3-HLF and TCF3-PBX1 positive B-cell acute lymphoblastic leukemia.Epigenomics. 2018 Feb;10(2):133-147. doi: 10.2217/epi-2017-0080. Epub 2018 Jan 15.
• [298] Inhibition of HOXB7 suppresses p27-mediated acute lymphoblastic leukemia by regulating basic fibroblast growth factor and ERK1/2.Life Sci. 2019 Feb 1;218:1-7. doi: 10.1016/j.lfs.2018.12.011. Epub 2018 Dec 8.
• [299] Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function.Hum Mutat. 2005 Apr;25(4):384-95. doi: 10.1002/humu.20155.
• [300] Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.J Natl Cancer Inst. 2008 Apr 16;100(8):580-95. doi: 10.1093/jnci/djn076. Epub 2008 Apr 8.
• [301] HLA complex-linked heat shock protein genes and childhood acute lymphoblastic leukemia susceptibility.Cell Stress Chaperones. 2010 Sep;15(5):475-85. doi: 10.1007/s12192-009-0161-6. Epub 2009 Dec 9.
• [302] ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.Blood Cells Mol Dis. 2016 Mar;57:30-4. doi: 10.1016/j.bcmd.2015.11.006. Epub 2015 Nov 15.
• [303] Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities.Blood Cells Mol Dis. 2011 Apr 15;46(4):321-6. doi: 10.1016/j.bcmd.2011.02.005. Epub 2011 Mar 17.
• [304] Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Case-Control and Family-Based Studies in Multiethnic Populations.Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1531-1539. doi: 10.1158/1055-9965.EPI-17-0360. Epub 2017 Jul 27.
• [305] The effect of adopting pediatric protocols in adolescents and young adults with acute lymphoblastic leukemia in pediatric vs adult centers: An IMPACT Cohort study.Cancer Med. 2019 May;8(5):2095-2103. doi: 10.1002/cam4.2096. Epub 2019 Mar 26.
• [306] KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia.Mol Cell Biol. 2012 Jul;32(14):2917-33. doi: 10.1128/MCB.00133-12. Epub 2012 May 21.
• [307] ABCC4 functional SNP in the 3' splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.Cancer Chemother Pharmacol. 2017 Jul;80(1):109-117. doi: 10.1007/s00280-017-3340-7. Epub 2017 May 26.
• [308] Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14).Oncogene. 2003 Mar 6;22(9):1418-24. doi: 10.1038/sj.onc.1206272.
• [309] Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia.Immunol Lett. 2009 Feb 21;122(2):185-92. doi: 10.1016/j.imlet.2008.12.008. Epub 2009 Feb 11.
• [310] Deregulation of linc-PINT in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells.Oncotarget. 2018 Feb 5;9(16):12842-12852. doi: 10.18632/oncotarget.24401. eCollection 2018 Feb 27.
• [311] Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment.Am J Cancer Res. 2017 Jun 1;7(6):1389-1406. eCollection 2017.
• [312] Aberrant expression of the LHX4 LIM-homeobox gene caused by t(1;14)(q25;q32) in chronic myelogenous leukemia in biphenotypic blast crisis.Genes Chromosomes Cancer. 2003 Nov;38(3):269-73. doi: 10.1002/gcc.10283.
• [313] DNA repair gene XRCC1 polymorphisms in childhood acute lymphoblastic leukemia.Cancer Lett. 2005 Jan 10;217(1):17-24. doi: 10.1016/j.canlet.2004.06.055.
• [314] Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.J Clin Oncol. 2012 Jul 1;30(19):2384-92. doi: 10.1200/JCO.2011.40.5936. Epub 2012 May 21.
• [315] MEIS1, PREP1, and PBX4 are differentially expressed in acute lymphoblastic leukemia: association of MEIS1 expression with higher proliferation and chemotherapy resistance.J Exp Clin Cancer Res. 2011 Dec 20;30(1):112. doi: 10.1186/1756-9966-30-112.
• [316] The study of METTL3 and METTL14 expressions in childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.Mol Genet Genomic Med. 2019 Oct;7(10):e00933. doi: 10.1002/mgg3.933. Epub 2019 Aug 20.
• [317] Molecular studies reveal a MLL-MLLT3 gene fusion displaced in a case of childhood acute lymphoblastic leukemia with complex karyotype.Cancer Genet. 2015 Apr;208(4):143-7. doi: 10.1016/j.cancergen.2015.02.002. Epub 2015 Feb 19.
• [318] Adult acute lymphoblastic leukemia phenotypes defined by monoclonal antibodies.Blood. 1985 Mar;65(3):730-5.
• [319] Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia.Chemotherapy. 2018 Apr 19;63(2):101-107. doi: 10.1159/000486823. Online ahead of print.
• [320] The association of folate pathway and DNA repair polymorphisms with susceptibility to childhood acute lymphoblastic leukemia.Gene. 2015 May 15;562(2):203-9. doi: 10.1016/j.gene.2015.02.077. Epub 2015 Mar 5.
• [321] NET1 Enhances Proliferation and Chemoresistance in Acute Lymphoblastic Leukemia Cells.Oncol Res. 2019 Aug 8;27(8):935-944. doi: 10.3727/096504019X15555388198071. Epub 2019 Apr 17.
• [322] Down regulation of membrane-bound Neu3 constitutes a new potential marker for childhood acute lymphoblastic leukemia and induces apoptosis suppression of neoplastic cells.Int J Cancer. 2010 Jan 15;126(2):337-49. doi: 10.1002/ijc.24733.
• [323] Alterations of deadenylase expression in acute leukemias: evidence for poly(a)-specific ribonuclease as a potential biomarker.Acta Haematol. 2012;128(1):39-46. doi: 10.1159/000337418. Epub 2012 May 17.
• [324] Promoter methylation-mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance.Genes Chromosomes Cancer. 2011 Dec;50(12):1043-53. doi: 10.1002/gcc.20922. Epub 2011 Aug 24.
• [325] Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.Pediatr Blood Cancer. 2017 Mar;64(3). doi: 10.1002/pbc.26259. Epub 2016 Sep 19.
• [326] Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.Exp Hematol. 2018 Jul;63:52-63.e5. doi: 10.1016/j.exphem.2018.04.002. Epub 2018 Apr 12.
• [327] Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia.J Cell Commun Signal. 2017 Jun;11(2):137-145. doi: 10.1007/s12079-016-0357-3. Epub 2016 Oct 24.
• [328] Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage.Exp Hematol. 2001 Jan;29(1):93-103. doi: 10.1016/s0301-472x(00)00620-2.
• [329] Deletion of the Miz-1 POZ Domain Increases Efficacy of Cytarabine Treatment in T- and B-ALL/Lymphoma Mouse Models.Cancer Res. 2019 Aug 15;79(16):4184-4195. doi: 10.1158/0008-5472.CAN-18-3038. Epub 2019 Jul 4.
• [330] BMI1 enhancer polymorphism underlies chromosome 10p12.31 association with childhood acute lymphoblastic leukemia.Int J Cancer. 2018 Dec 1;143(11):2647-2658. doi: 10.1002/ijc.31622. Epub 2018 Oct 3.
• [331] Prolonged versus standard native E. coli asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951.Haematologica. 2017 Oct;102(10):1727-1738. doi: 10.3324/haematol.2017.165845. Epub 2017 Jul 27.
• [332] ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.Oncogene. 2006 Mar 23;25(13):1862-70. doi: 10.1038/sj.onc.1209236.
• [333] Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes.BMC Cancer. 2015 Jul 23;15:539. doi: 10.1186/s12885-015-1549-6.
• [334] Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
• [335] A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.Oncotarget. 2017 Jan 31;8(5):7477-7488. doi: 10.18632/oncotarget.13936.
• [336] miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia.Leuk Res. 2012 Sep;36(9):1098-104. doi: 10.1016/j.leukres.2012.05.003. Epub 2012 Jun 6.
• [337] PTPRG inhibition by DNA methylation and cooperation with RAS gene activation in childhood acute lymphoblastic leukemia.Int J Cancer. 2014 Sep 1;135(5):1101-9. doi: 10.1002/ijc.28759. Epub 2014 Feb 19.
• [338] Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia.BMC Cancer. 2013 Oct 5;13:457. doi: 10.1186/1471-2407-13-457.
• [339] Residual methylation of tumor suppressor gene promoters, RASSF6 and RASSF10, as novel biomarkers for minimal residual disease detection in adult acute lymphoblastic leukemia.Ann Hematol. 2019 Dec;98(12):2719-2727. doi: 10.1007/s00277-019-03775-y. Epub 2019 Sep 5.
• [340] A childhood acute lymphoblastic leukemia genome-wide association study identifies novel sex-specific risk variants.Medicine (Baltimore). 2016 Nov;95(46):e5300. doi: 10.1097/MD.0000000000005300.
• [341] Posterior circulation involvement and collateral flow pattern in moyamoya disease with the RNF213 polymorphism.Childs Nerv Syst. 2019 Feb;35(2):309-314. doi: 10.1007/s00381-018-3985-5. Epub 2018 Oct 3.
• [342] A translocation in acute lymphoblastic leukemia that cytogenetically mimics the recurrent MLL-AFF1 translocation and fuses SEPT11 to MLL.Cancer Genet Cytogenet. 2010 Aug;201(1):48-51. doi: 10.1016/j.cancergencyto.2010.05.002.
• [343] The CDCREL1 gene fused to MLL in de novo acute myeloid leukemia with t(11;22)(q23;q11.2) and its frequent expression in myeloid leukemia cell lines.Genes Chromosomes Cancer. 2001 Mar;30(3):230-5. doi: 10.1002/1098-2264(2000)9999:9999<::aid-gcc1084>3.0.co;2-j.
• [344] NUP214 in Leukemia: It's More than Transport.Cells. 2019 Jan 21;8(1):76. doi: 10.3390/cells8010076.
• [345] Association of SHMT1 gene polymorphisms with the risk of childhood acute lymphoblastic leukemia in a sample of Iranian population.Cell Mol Biol (Noisy-le-grand). 2016 Feb 29;62(2):45-51.
• [346] Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia.Hum Mol Genet. 2014 Feb 1;23(3):590-601. doi: 10.1093/hmg/ddt447. Epub 2013 Sep 17.
• [347] Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.Eur J Haematol. 2014 Mar;92(3):263-7. doi: 10.1111/ejh.12234. Epub 2013 Nov 28.
• [348] Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway.Biomed Pharmacother. 2019 Jul;115:108913. doi: 10.1016/j.biopha.2019.108913. Epub 2019 May 1.
• [349] Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).Genes Chromosomes Cancer. 2015 Jul;54(7):401-8. doi: 10.1002/gcc.22251. Epub 2015 May 7.
• [350] Overexpression of SORCIN is a Prognostic Biomarker for Multidrug-Resistant Pediatric Acute Lymphoblastic Leukemia and Correlates with Upregulated MDR1/P-gp.Genet Test Mol Biomarkers. 2016 Sep;20(9):516-21. doi: 10.1089/gtmb.2016.0031. Epub 2016 Jul 6.
• [351] Adenosine Deaminase 1 as a Biomarker for Diagnosis and Monitoring of Patients with Acute Lymphoblastic Leukemia.J Med Biochem. 2018 Apr 1;37(2):128-133. doi: 10.1515/jomb-2017-0042. eCollection 2018 Apr.
• [352] Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children.J Natl Cancer Inst. 2019 Dec 1;111(12):1350-1357. doi: 10.1093/jnci/djz043.
• [353] Promoter analysis of TFPT (FB1), a molecular partner of TCF3 (E2A) in childhood acute lymphoblastic leukemia.Biochem Biophys Res Commun. 2001 Nov 16;288(5):1250-7. doi: 10.1006/bbrc.2001.5906.
• [354] Investigation of copy-number variations of C8orf4 in hematological malignancies.Med Oncol. 2011 Dec;28 Suppl 1:S647-52. doi: 10.1007/s12032-010-9698-6. Epub 2010 Sep 29.
• [355] Rearrangements of the T cell receptor delta gene in T acute lymphoblastic leukemia cells are distinct from those occurring in B lineage acute lymphoblastic leukemia and preferentially involve one V delta gene segment.J Immunol. 1989 May 1;142(9):3305-11.
• [356] Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.Mol Cancer Ther. 2017 Jul;16(7):1401-1411. doi: 10.1158/1535-7163.MCT-17-0099. Epub 2017 Apr 26.
• [357] TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.Leuk Res. 2018 Nov;74:42-46. doi: 10.1016/j.leukres.2018.09.010. Epub 2018 Sep 26.
• [358] Antiproliferative Effect of Gaillardin from Inula oculus-christi in Human Leukemic Cells.Nutr Cancer. 2020;72(6):1043-1056. doi: 10.1080/01635581.2019.1665188. Epub 2019 Sep 23.
• [359] Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL).Leuk Res. 2006 Jul;30(7):883-9. doi: 10.1016/j.leukres.2005.11.012. Epub 2006 Jan 6.
• [360] Treatment of childhood acute lymphoblastic leukemia with delayed first intrathecal therapy and omission of prophylactic cranial irradiation: Results of the TPOG-ALL-2002 study.Cancer. 2018 Dec 1;124(23):4538-4547. doi: 10.1002/cncr.31758. Epub 2018 Oct 10.
• [361] Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.Oncogene. 2013 May 16;32(20):2586-91. doi: 10.1038/onc.2012.263. Epub 2012 Jul 2.
• [362] Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.Cancer Cell. 2018 Dec 10;34(6):906-921.e8. doi: 10.1016/j.ccell.2018.11.002.
• [363] Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia.Leuk Res. 2015 Dec;39(12):1455-61. doi: 10.1016/j.leukres.2015.10.006. Epub 2015 Oct 20.
• [364] EXT1, Regulated by MiR-665, Promotes Cell Apoptosis via ERK1/2 Signaling Pathway in Acute Lymphoblastic Leukemia.Med Sci Monit. 2019 Aug 29;25:6491-6503. doi: 10.12659/MSM.918295.
• [365] A unique phenotype of T-cell acute lymphoblastic leukemia in a patient with GATA2 haploinsufficiency.Pediatr Blood Cancer. 2019 Jun;66(6):e27649. doi: 10.1002/pbc.27649. Epub 2019 Feb 25.
• [366] HAP1 loss confers l-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway.Blood. 2019 May 16;133(20):2222-2232. doi: 10.1182/blood-2018-12-890236. Epub 2019 Feb 28.
• [367] Multiple sclerosis risk markers in HLA-DRA, HLA-C, and IFNG genes are associated with sex-specific childhood leukemia risk.Autoimmunity. 2010 Dec;43(8):690-7. doi: 10.3109/08916930903567492.
• [368] Contributions of IKZF1, DDC, CDKN2A, CEBPE, and LMO1 Gene Polymorphisms to Acute Lymphoblastic Leukemia in a Yemeni Population.Genet Test Mol Biomarkers. 2017 Oct;21(10):592-599. doi: 10.1089/gtmb.2017.0084. Epub 2017 Aug 2.
• [369] Association of methylenetetrahydrofolate dehydrogenase 1 polymorphisms with cancer: a meta-analysis.PLoS One. 2013 Jul 19;8(7):e69366. doi: 10.1371/journal.pone.0069366. Print 2013.
• [370] A rare polymorphic variant of NBS1 reduces DNA repair activity and elevates chromosomal instability.Cancer Res. 2014 Jul 15;74(14):3707-15. doi: 10.1158/0008-5472.CAN-13-3037. Epub 2014 May 15.
• [371] IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.PLoS Med. 2016 Dec 20;13(12):e1002200. doi: 10.1371/journal.pmed.1002200. eCollection 2016 Dec.
• [372] An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.Oncogene. 2019 Jan;38(5):671-686. doi: 10.1038/s41388-018-0474-y. Epub 2018 Aug 31.
• [373] Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia.Epigenomics. 2018 Jan;10(1):59-69. doi: 10.2217/epi-2017-0092. Epub 2017 Oct 10.
• [374] Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study.Biol Blood Marrow Transplant. 2016 Mar;22(3):423-31. doi: 10.1016/j.bbmt.2015.09.029. Epub 2015 Oct 9.
• [375] CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.Ann Hematol. 2011 Mar;90(3):293-9. doi: 10.1007/s00277-010-1085-z. Epub 2010 Sep 28.
• [376] Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias.Clin Chim Acta. 2012 Oct 9;413(19-20):1542-8. doi: 10.1016/j.cca.2012.06.025. Epub 2012 Jun 29.
• [377] Phosphorylation of serine/arginine-rich splicing factor 1 at tyrosine 19 promotes cell proliferation in pediatric acute lymphoblastic leukemia.Cancer Sci. 2018 Dec;109(12):3805-3815. doi: 10.1111/cas.13834. Epub 2018 Nov 14.
• [378] Methylation level of CpG islands in GGH gene promoter in pediatric acute leukemia.PLoS One. 2017 Mar 9;12(3):e0173472. doi: 10.1371/journal.pone.0173472. eCollection 2017.